| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/II data readout example | Phase 1 | — | Subscribe to access the data. | Gene Therapies | Nervous System | ||
Phase 1/II data readout example | Phase 1 | — | Subscribe to access the data. | Gene Therapies | Nervous System | ||
Phase 1/II data readout example | Phase 1 | — | Subscribe to access the data. | Gene Therapies | Nervous System |
Recent Updates
Recently added Catalysts
uniQure N.V.$42.63
-1.41 (-3.17%)
D 31Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.51 B
EPS
-3.51
P/E Ratio
-
Value Trade
84.91 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
3.56 M
R&D Expenses
29.18 M
Operating CF
-38.24 M
Total Assets
778.71 M
Total Liabilities
629.36 M
Equity
149.34 M
D/E Ratio
12,345
-11.72 %
Week
36.59 %
1 Month
1.38 %
3 Month
-12.92 %
6 Month
-30.15 %
5 Year
42.29 %
All Time
Cash Data
Cash Position
141.54 M
Monthly Burn
12.75 M
Runway
9.1 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
1.14 M
52 Week Range
8.73 - 71.50
% held by Insiders
9.76 %
% held by Institutions
83.47 %
Enterprise Value
1.47 B
Total Shares
62.51 M
Short %
20.57 %
Float Shares
55.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for uniQure N.V.
1177Total events
7Upcoming
222Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 7
Event history 1170
Q3 2026
◆BLA SubmissionAMT-130Regulatory Filing
Company intends to submit BLA for AMT-130 in Q3 2026
Huntington's diseasesource ↗
Q3 2026
●EU MAA SubmissionAMT-130Ex-US Regulatory
UK MAA submission for AMT-130 expected in Q3 2026
Huntington's diseasesource ↗
Q3 2026
◆Timing GuidanceAMT-130Presentation
Four-year analysis of AMT-130 expected in Q3 2026
Huntington's diseasesource ↗
Q3 2026
Jun 23, 2026
▼Equity OfferingCorporate
Pricing of upsized $225 million public offering of 4,945,055 ordinary shares at $45.50 per share
Jun 22, 2026
▼Equity OfferingCorporate
Commencement of $150 million underwritten public offering of ordinary shares and pre-funded warrants
Jun 19, 2026
◆Oral PresentationAMT-260Presentation
Presentation of initial six-month follow-up data on first cohort at Epilepsy Foundation Pipeline Conference
refractory mesial temporal lobe epilepsysource ↗
Jun 18, 2026
◆Oral PresentationAMT-260Presentation
Clinical update from first cohort at Epilepsy Foundation Pipeline Conference
refractory mesial temporal lobe epilepsysource ↗
Jun 17, 2026
▲Type B MeetingAMT-130FDA Meeting
FDA Type B meeting: FDA communicated 3-year analysis acceptable as primary basis for BLA for accelerated approval
Huntington's diseasesource ↗
Jun 2026
◆Enrollment CompleteAMT-260Trial
Enrollment completion expected for second cohort
refractory mesial temporal lobe epilepsysource ↗
May 5, 2026
Apr 30, 2026
▲MHRA MilestoneAMT-130Ex-US Regulatory
Successful UK MHRA Pre-Submission Meeting for AMT-130
Huntington's diseasesource ↗
Drug Pipeline Intelligence
D31
Pipeline Score $67M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.0x
rNPV / MCap Top 37%
Micro Cap (rank 575 of 911)
Percentile RankuniQure N.V. faces pipeline headwinds (31/100), with $262M risk-adjusted pipeline value, led by AMT-191 in Fabry Disease (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMT-191 Small molecule | Fabry Disease | Phase 1 | NCT06270316 | 31% | $128M | RECRUITING | 12 | STALLED | D (34) | Apr 30, 2031 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AMT-260 | refractory mesial temporal lobe epilepsy | Phase 1/2a | 2026-06-19 | three out of six patients experienced significant reductions in seizures; ranging from a 79% to 100% decline from baseline; the remaining three patients experienced variable changes in disabling seizures ranging from a 33% decrease to a 36% increase compared to baseline Read More | uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy Read More | |
AMT-260 | refractory mesial temporal lobe epilepsy | Phase 1/2a | 2026-06-19 | three out of six patients experienced significant reductions in seizures; ranging from a 79% to 100% decline from baseline; the remaining three patients experienced variable changes in disabling seizures ranging from a 33% decrease to a 36% increase compared to baseline Read More | uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy Read More | |
AMT-260 | refractory mesial temporal lobe epilepsy | Phase 1/2a | 2026-06-19 | three out of six patients experienced significant reductions in seizures; ranging from a 79% to 100% decline from baseline; the remaining three patients experienced variable changes in disabling seizures ranging from a 33% decrease to a 36% increase compared to baseline Read More | uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QURE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QURE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QUREuniQure Announces Pricing of Upsized $225 Million Public Offering
uniQure N.V. has priced its public offering of 4,945,055 ordinary shares at $45.50 each, aiming to raise approximately $225 million. The offering is set to close around June 25, 2026, pending customary conditions. The company is recognized for its advancements in gene therapy, particularly for severe medical needs.
Read more →QURE▲ +10.5%on this newsshared move
uniQure Announces $150 Million Proposed Public Offering
uniQure N.V. has announced a proposed public offering of $150 million of its ordinary shares, with an additional option for underwriters to purchase $22.5 million more. The offering is subject to market conditions, and there is uncertainty regarding its completion and terms. This move aims to bolster the company's financial resources for advancing its gene therapy pipeline.
Read more →QUREuniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
uniQure has announced preliminary data from its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy. The initial results show that three out of six patients experienced significant reductions in seizures, while the remaining patients had variable responses. The treatment was well-tolerated with no serious adverse events reported, supporting further evaluation of AMT-260.
Read more →QURE▲ +78.4%on this newsshared move
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
uniQure announced plans to submit a Biologics License Application (BLA) for AMT-130, a gene therapy for Huntington's disease, based on a 3-year analysis from its Phase I/II study. The FDA has indicated this data is acceptable for accelerated approval. The company aims to submit the BLA by Q3 2026 and is aligning on the confirmatory study design with the FDA.
Read more →QUREuniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
uniQure reported its Q1 2026 financial results, highlighting advancements in its gene therapy pipeline, particularly AMT-130 for Huntington's disease and AMT-191 for Fabry disease. The company has scheduled a Type B meeting with the FDA and expects to submit a Marketing Authorization Application in the UK. Despite a strong cash position, the company faces challenges with regulatory feedback and safety concerns in ongoing trials.
Read more →QURE▲ +19.2%on this newsshared move
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
uniQure announced a successful Pre-Submission Meeting with the UK's MHRA regarding AMT-130 for Huntington's disease. The company plans to submit a Marketing Authorization Application in Q3 2026, supported by promising trial data showing a 75% slowing of disease progression. Additionally, a Type B meeting with the U.S. FDA is scheduled to discuss Phase III trial design.
Read more →QUREuniQure to Announce First Quarter 2026 Financial Results
uniQure N.V. will announce its first quarter 2026 financial results on May 5, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results. The event will be available via webcast, and a replay will be accessible for 90 days. Analysts can join the call by dialing in with a specific conference ID.
Read more →QURE▼ -5.6%on this news
UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th
A class action lawsuit has been initiated against uniQure N.V. for alleged misleading statements made during the company’s pivotal study period. Investors who purchased shares between September 24 and October 31, 2025, are encouraged to participate in the lawsuit. The complaint details significant concerns about the study's FDA approval status and the potential need to delay the Biologics License Application due to additional studies. Investors have until April 13, 2026, to apply for lead plaintiff status.
Read more →QUREuniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE
ClaimsFiler has notified investors of a lead plaintiff deadline in a class action lawsuit against uniQure N.V. for losses incurred between September and October 2025. Investors are encouraged to file claims as uniQure is accused of failing to disclose critical information regarding their drug AMT-130. This revelation led to a dramatic drop in share price by over 49% in November 2025, following the disclosure that the FDA questioned the adequacy of data for a Biologics License Application. The case is currently pending in the Southern District of New York.
Read more →QURE▼ -7.3%on this newsshared move
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
uniQure N.V. is facing a securities fraud class action lawsuit following a substantial delay in FDA approval for its drug candidate, AMT-130. The company's shares fell by more than 49% after the FDA indicated that data from Phase I/II studies may not support a Biologics License Application. Investors who suffered losses during the class period have until April 13, 2026, to file as lead plaintiffs. This legal action reflects broader concerns about the company's disclosure practices and the regulatory process for its leading drug candidate.
Read more →QUREUNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE
Rosen Law Firm is encouraging investors of uniQure N.V. who experienced losses exceeding $100,000 to join a securities class action lawsuit by the April 13, 2026, deadline. The lawsuit alleges that the company misrepresented the approval status of its Pivotal Study for a treatment related to Huntington's Disease and downplayed potential delays in its BLA application timeline. The law firm emphasizes the importance of selecting qualified legal counsel given their success in achieving large settlements for investors in past cases. Investors have the option to serve as lead plaintiffs or to select counsel of their choice.
Read more →QUREUNIQURE N.V. (NASDAQ: QURE) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by April 13, 2026
A class action lawsuit has been initiated against uniQure N.V. on behalf of investors who acquired its securities between September 24, 2025, and October 31, 2025. The plaintiff alleges that the company misled investors regarding the effectiveness of its gene therapy candidate AMT-130 and the certainty of accelerated FDA approval. Following a significant rise in stock price, investors learned that key agreements with the FDA were not finalized, resulting in a drastic drop in the stock value. Investors interested in participating in the class action must act by April 13, 2026.
Read more →QUREUNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th
A class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) by Bragar Eagel & Squire, P.C. for misleading investors. The lawsuit claims that during the specified Class Period, the company made materially false statements concerning its business and operations. Investors who acquired shares between September and October 2025 are urged to act before the April 13, 2026 deadline to apply as lead plaintiff. Significant concerns include unapproved study designs that may affect the Biologics License Application timeline.
Read more →QUREUNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline
Bernstein Liebhard LLP has reminded uniQure N.V. (QURE) investors of an upcoming deadline regarding a securities fraud class action lawsuit. The lawsuit alleges that the company and its senior officers made misrepresentations about AMT-130, a drug intended for Huntington's Disease treatment. Investors who acquired shares between September 24, 2025, and October 31, 2025, may be eligible to join the lawsuit, with a lead plaintiff application due by April 13, 2026. Participation is on a contingency fee basis with no fees for shareholders.
Read more →QUREUNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE
Rosen Law Firm is reminding investors of uniQure N.V. to secure representation before the April 13, 2026, lead plaintiff deadline in a class action lawsuit. The case alleges that uniQure misrepresented data regarding its pivotal study for a drug candidate in Huntington's Disease. Investors who purchased shares during the designated class period may be entitled to compensation at no upfront cost. The firm emphasizes the importance of selecting qualified counsel in these proceedings.
Read more →QURE▲ +7.8%on this newsshared move
uniQure N.V. (QURE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
uniQure N.V. is facing a securities fraud class action lawsuit filed by Kessler Topaz Meltzer & Check, LLP, representing investors who purchased shares between September 24 and October 31, 2025. The lawsuit accuses the company of making materially false statements regarding its Huntington's disease gene therapy, AMT-130, and failing to disclose significant information about FDA approval processes. After the company revealed that its clinical trial data might not support its Biologics License Application, its stock plummeted over 49%. Investors are advised to consider filing for lead plaintiff status by April 13, 2026.
Read more →QURE▲ +5.4%on this newsshared move
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline
uniQure N.V. is facing a securities fraud class action lawsuit filed by Kessler Topaz Meltzer & Check, LLP on behalf of investors. The lawsuit covers the class period from September 24, 2025, to October 31, 2025, and alleges that the company made materially false statements about its Huntington's disease gene therapy drug, AMT-130. Following disclosures regarding the FDA's stance on the submission timelines and clinical trial results, uniQure's share price fell by more than 49%. Investors have until April 13, 2026, to seek lead plaintiff status.
Read more →QUREUNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against uniQure N.V. on behalf of stockholders who suffered losses between September 24 and October 31, 2025. The lawsuit claims that uniQure made materially false statements regarding the approval of its pivotal study design by the FDA, and downplayed risks related to potential delays in its Biologics License Application (BLA) timeline. Investors can apply to be lead plaintiffs until April 13, 2026, and are encouraged to reach out for more information on their legal rights.
Read more →QURE▲ +34%on this news· ran to +69% by day 1shared move
uniQure N.V. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your Rights – QURE
uniQure N.V. has been sued for securities law violations based on allegations that the company made materially false statements regarding its clinical trial results and the approval status of its study design by the FDA. The lawsuit also suggests that uniQure did not adequately disclose the potential delays in its Biologics License Application timeline due to the need for additional studies. Shareholders who purchased stock during the specified period are encouraged to contact the Gross Law Firm for potential recovery options.
Read more →QURE▲ +34%on this news· ran to +69% by day 1shared move
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
A securities fraud class action lawsuit has been filed against uniQure N.V. by Kessler Topaz Meltzer & Check, LLP, concerning allegations of material misstatements regarding the company's gene therapy drug for Huntington's disease. The lawsuit pertains to investors who acquired shares during a specific class period from September 24, 2025, to October 31, 2025. Following revelations about issues with the drug's trial and related FDA submission, uniQure's share price fell dramatically, leading to investor losses. A deadline to seek lead plaintiff status in the lawsuit is set for April 13, 2026.
Read more →QURE▼ -32.8%on this newsshared move
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
uniQure reported its 2025 financial results and highlighted advancements in its gene therapy programs. The company is evaluating Phase III development for AMT-130, which has shown significant efficacy in Huntington's disease. Additionally, AMT-260 and AMT-191 are progressing with promising early data. However, regulatory challenges remain, particularly with the FDA's recommendations for AMT-130.
Read more →QURE▼ -32.8%on this newsshared move
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
uniQure announced a regulatory update regarding AMT-130, its investigational gene therapy for Huntington's disease. The FDA indicated that the existing Phase I/II data is insufficient for a marketing application and recommended a new randomized study. uniQure plans to continue discussions with the FDA and request a Type B meeting to explore potential study designs.
Read more →QURE▼ -32.8%on this newsshared move
uniQure N.V. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 13, 2026 to Discuss Your Rights – QURE
Levi & Korsinsky, LLP has announced a class action securities lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who experienced losses due to alleged fraud between September 24 and October 31, 2025. The lawsuit claims that uniQure's study design was not fully FDA-approved and that key results were misrepresented, potentially necessitating a delay in the company's Biologics License Application. Affected investors have until April 13, 2026, to request to be appointed as lead plaintiffs in the suit.
Read more →QUREuniQure to Announce 2025 Financial Results
uniQure N.V. will announce its fourth quarter and full year 2025 financial results on March 2, 2026. Following the announcement, a conference call will be held at 8:00 a.m. ET, accessible via a live webcast. Analysts can participate in a Q&A session by calling in with a provided conference ID.
Read more →QURE▲ +6.1%on this newsshared move
UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
A shareholder has initiated a class action lawsuit against uniQure N.V. on behalf of investors who acquired its shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that the company made false representations about AMT-130, a drug aimed at treating Huntington's Disease. Investors are being encouraged to take action by filing as lead plaintiffs by April 13, 2026, although they can still participate in any recovery as absent class members. Bernstein Liebhard LLP, the law firm handling the case, operates on a contingency basis, meaning no fees are charged to shareholders upfront.
Read more →QURE▼ -5.1%on this news· ran to -21% by day 3shared move
UNIQURE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against uniQure N.V. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against uniQure N.V. by Bragar Eagel & Squire, P.C. on behalf of investors who acquired shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that the company made materially false and misleading statements regarding its business and operations, particularly around the FDA's approval of its Pivotal Study design. Investors have until April 13, 2026, to apply as lead plaintiffs in the case, which suggests potential further delays in the company’s Biologics License Application (BLA) submission.
Read more →QUREuniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
uniQure has released updated preliminary data from its Phase I/IIa trial of AMT-191 for Fabry disease, showing sustained increases in α-Gal A enzyme activity in all patients. Six out of eleven patients have successfully discontinued enzyme replacement therapy. The therapy demonstrated a manageable safety profile, although some patients experienced liver enzyme elevations, leading to a pause in higher dose cohorts for further assessment.
Read more →QUREUNIQURE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V. on Behalf of uniQure Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating uniQure N.V. on behalf of its stockholders due to potential legal claims related to federal securities law violations. This investigation follows uniQure's November 2025 press release, which revealed that the FDA does not consider data from their Phase I/II studies adequate for a BLA submission. Consequently, the company has stated that the timing for this submission is now uncertain, leading to a drastic drop in stock value. Investors affected by these developments are encouraged to contact the law firm for legal support.
Read more →QURE▼ -6.7%on this news
LEADERSHIP IN GENE THERAPY JANUARY 2026 | 2 Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”
uniQure is reinforcing its position as a leader in gene therapy with a strong financial standing, highlighted by approximately $694.2 million in cash as of September 2025. The company has made progress in clinical trials, including promising data for AMT-130, aimed at treating Huntington's disease, and plans for upcoming data readouts for AMT-260 and AMT-191 in 2026. Engagements with the FDA for Biologics License Application pathways are ongoing, reflecting a focused approach toward commercialization. Although some adverse events were noted, the overall clinical profiles remain encouraging.
Read more →QURE▲ +9.4%on this newsshared move
uniQure Announces Type A Meeting Scheduled with FDA
uniQure has announced a Type A meeting with the FDA to discuss the Biologics License Application for AMT-130, a gene therapy aimed at treating Huntington's disease. The company emphasizes the urgent need for effective therapies in this area and is committed to working closely with the FDA. A regulatory update will follow after the meeting.
Read more →QUREuniQure Notice of Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating uniQure N.V. for potential violations of federal securities laws following a significant stock price drop. On November 3, 2025, uniQure announced that the FDA found its AMT-130 gene therapy data insufficient for a Biologics License Application. As a result, the company faced over a 50% decline in stock value, and uncertainties arose regarding the timing of future BLA submissions for AMT-130.
Read more →QUREData Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
The five-year results from the Phase 3 HOPE-B study confirm the long-term durability and safety of HEMGENIX (etranacogene dezaparvovec-drlb) for adults with hemophilia B. Published in the NEJM, the data show sustained therapeutic benefits, including a 94% rate of freedom from prophylaxis treatment and strong factor IX activity levels. HEMGENIX remains the only gene therapy available for this condition.
Read more →QURE▼ -10.8%on this newsshared move
uniQure Provides Regulatory Update on AMT-130 for Huntington ' s Disease Lexington, MA and Amsterdam, the Netherlands
uniQure N.V. has provided an update on its investigational gene therapy AMT-130 for Huntington's disease. Following a meeting with the FDA, the company is advised that data from its Phase I/II studies may not be sufficient for a Biologics License Application. As a response, uniQure plans to request a follow-up meeting with the FDA in early 2026. The company remains committed to collaboration with regulatory authorities and emphasizes the pressing need for effective treatments within the Huntington's disease community.
Read more →QURE▼ -5.9%on this news
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
uniQure reported its Q3 2025 financial results, highlighting significant progress in its clinical programs, particularly with AMT-130 for Huntington's disease, which met key endpoints. The company also received unexpected feedback from the FDA regarding its BLA submission, prompting a need for urgent discussions. Financially, uniQure raised $323.7 million, enhancing its cash reserves to $694.2 million.
Read more →QURE▲ +5.6%on this news· ran to +18% by day 3shared move
uniQure to Announce Third Quarter 2025 Financial Results
uniQure N.V. will announce its third quarter 2025 financial results on November 10, 2025, before market open. Following the announcement, a conference call will be held at 8:30 a.m. ET, which will also be available via webcast. Analysts can participate in the Q&A session by calling in with a passcode.
Read more →QURE▼ -14.4%on this newsshared move
UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V. on Behalf of uniQure Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation into uniQure N.V. on behalf of stockholders following significant losses. The investigation stems from a recent press release where uniQure disclosed that the FDA may no longer consider data from its Phase I/II studies adequate for a Biologics License Application submission for AMT-130. As a result, shares of uniQure experienced a drastic decline of over 57%. The firm encourages affected investors to discuss their legal rights and potential claims.
Read more →QURE▼ -11.2%on this news· ran to -24% by day 1shared move
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (QURE)
Kirby McInerney LLP is investigating potential claims against uniQure N.V. for securities fraud, focusing on the company's management practices. This comes after uniQure disclosed that the FDA no longer believes the data from Phase I/II studies of AMT-130 meets the necessary criteria for a Biologics License Application (BLA) submission. Consequently, the timeline for the BLA submission is now uncertain, severely impacting the company's stock price, which plummeted by approximately 49.33% shortly after the announcement.
Read more →QUREuniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
uniQure N.V. has successfully closed an upsized public offering, selling 6,736,841 ordinary shares at $47.50 each, raising around $345 million. The offering included additional shares purchased by underwriters and pre-funded warrants. The funds will support commercialization readiness for AMT-130 and other clinical developments. The offering was managed by several financial institutions.
Read more →QUREuniQure Announces Pricing of Upsized $300 Million Public Offering
uniQure N.V. has announced the pricing of its public offering of 5,789,473 ordinary shares at $47.50 each, aiming to raise around $300 million. The offering is set to close on or about September 29, 2025, pending customary conditions. The company continues to advance its gene therapy pipeline for various severe diseases.
Read more →QURE▲ +10.8%on this news· ran to +23% by day 3shared move
uniQure Announces $200 Million Proposed Public Offering
uniQure N.V. has announced a proposed public offering of $200 million in ordinary shares and pre-funded warrants. The offering is underwritten and includes a 30-day option for underwriters to purchase additional shares. The completion of the offering is subject to market conditions, and the final terms will be disclosed in a prospectus supplement.
Read more →QURE▲ +247.7%on this news· ran to +335% by day 3shared move
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
uniQure N.V. has announced a $175 million non-dilutive senior secured term loan facility with Hercules Capital. This refinancing extends the term of existing debt to October 2030 and provides access to additional funds to support the potential commercial launch of AMT-130 for Huntington's disease. The transaction aims to enhance the company's financial flexibility and reduce capital costs.
Read more →QURE▲ +247.7%on this news· ran to +335% by day 3shared move
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
uniQure announced positive topline results from its pivotal Phase I/II study of AMT-130 for Huntington's disease. The study met its primary endpoint, showing a significant 75% slowing of disease progression at 36 months. Additionally, AMT-130 demonstrated favorable trends in secondary endpoints and was well-tolerated. The company plans to submit a Biologics License Application in early 2026.
Read more →QUREuniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
uniQure has announced promising initial data from its Phase I/IIa trial of AMT-191 for Fabry disease, showing significant increases in α-Gal A enzyme activity among all patients in the first cohort. All patients were able to discontinue enzyme replacement therapy, indicating the potential effectiveness of AMT-191. The treatment exhibited a manageable safety profile, with further results expected in 2026.
Read more →QURE▼ -8.7%on this news
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA s
uniQure N.V. reported its financial results for Q2 2025, highlighting significant progress with its AMT-130 program, including FDA alignment for a BLA submission expected in early 2026. The company showed promising early clinical results for AMT-260 in treating refractory epilepsy and appointed a new Chief Customer and Strategy Officer. Although revenues decreased from the same period last year, uniQure's cash reserves are projected to sustain operations into late 2027. CEO Matt Kapusta expressed optimism about the company's future trajectory and ongoing programs.
Read more →QUREuniQure to Announce Second Quarter 2025 Financial Results
uniQure N.V. (NASDAQ: QURE) will report its second quarter 2025 financial results on July 29, 2025, before market open. Following the announcement, a conference call will take place at 8:30 a.m. ET. The company is recognized for its gene therapy advancements, particularly its historic treatment for hemophilia B, and is developing additional therapies targeting conditions such as Huntington's disease and ALS.
Read more →QUREuniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
uniQure N.V. has appointed Kylie O’Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In her new role, she will oversee the global commercialization strategy for AMT-130, the company's investigational gene therapy for Huntington's disease. O'Keefe brings significant experience from her previous role at PTC Therapeutics and is expected to play a crucial part in transitioning uniQure into a commercial-stage biotechnology company. The company is aiming for a potential U.S. launch of AMT-130 in 2026, which could mark a significant breakthrough in Huntington's disease treatment.
Read more →QUREuniQure Provides Regulatory Update on AMT-130 for Huntington's Disease ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today
uniQure N.V. announced a regulatory update on its gene therapy AMT-130 for Huntington's disease, stating alignment with the FDA supports its plan for a Biologics License Application (BLA) submission in Q1 2026. The company has received positive feedback regarding its statistical analysis plan and Chemistry, Manufacturing, and Controls (CMC) requirements. AMT-130 aims to become the first disease-modifying therapy for Huntington's disease, utilizing a rigorous approach backed by multiple years of clinical data. A conference call is scheduled to provide further details and share three-year top-line data in Q3 2025.
Read more →QUREuniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
uniQure N.V. has presented promising results from the first patient dosed with its investigational gene therapy, AMT-260, for refractory mesial temporal lobe epilepsy (MTLE). The patient experienced a 92% reduction in seizure frequency and reported no serious adverse events over a five-month follow-up period. This data was shared at the Epilepsy Therapies & Diagnostics Development Symposium, highlighting the potential of AMT-260 as a new treatment option for patients with drug-resistant MTLE. The ongoing Phase I/IIa trial continues to seek additional participants to further assess the therapy's efficacy and safety.
Read more →QUREuniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ AMT-130 granted Breakthrough Therapy designation by FDA~ ~ Initial safety data from third cohort of Phase I/II study show
uniQure N.V. reported its financial results for the first quarter of 2025, highlighting significant milestones such as the FDA granting Breakthrough Therapy designation for AMT-130. Initial safety data from the Phase I/II trial shows the therapy is generally well-tolerated. The company holds a strong cash position, expected to fund operations into late 2027, as it prepares for potential commercialization and regulatory updates. However, the firm reported a revenue decline and a substantial net loss compared to the previous year.
Read more →QURE▲ +7.6%on this news· ran to -22% by day 1
uniQure to Announce First Quarter 2025 Financial Results
uniQure N.V. will announce its first quarter 2025 financial results on May 9, 2025, before the market opens. The company is advancing its gene therapy pipeline, including AMT-130, towards a Biologics License Application (BLA) submission. This upcoming earnings call will enhance transparency with the investment community, following the significant achievements in gene therapies for conditions such as hemophilia B.
Read more →QURE▲ +38.4%on this news· ran to +53% by day 3
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. has announced that the FDA granted Breakthrough Therapy designation to its gene therapy AMT-130 for Huntington's disease, a significant milestone for the treatment of this neurodegenerative disorder. This designation is based on promising results from ongoing Phase I/II trials that demonstrate AMT-130's potential to slow disease progression. The company anticipates detailed regulatory guidance for submitting a Biologics License Application by the second quarter of 2025. AMT-130 is also supported by multiple other designations from the FDA, highlighting its potential as a groundbreaking therapeutic option.
Read more →QUREuniQure Announces 2024 Financial Results and Highlights Recent Company Progress ~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Hu
uniQure has reported its 2024 financial results, highlighting significant progress, particularly with AMT-130 for Huntington's disease, where it secured alignment with the FDA on the Accelerated Approval pathway. The company has completed patient enrollment in various clinical trials and initiated preparations for a Biologics License Application. Despite a reduction in cash reserves, the company expects its funds to sustain operations through the second half of 2027. It also noted a decrease in net loss compared to the previous year, indicating improved financial management.
Read more →QUREuniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure N.V. announced the completion of enrollment in the first cohort of its Phase I/IIa clinical trial for AMT-191, a gene therapy for Fabry disease. The Independent Data Monitoring Committee reviewed the initial safety data and recommended proceeding to the second cohort, indicating no significant safety concerns. The company plans to start enrollment of this second cohort in the first quarter of 2025. AMT-191 represents a novel approach to treating Fabry disease, which currently lacks effective solutions.
Read more →QUREuniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
uniQure N.V. has received a favorable recommendation from the Independent Data Monitoring Committee for its Phase I/II clinical trial of AMT-162, which targets SOD1-ALS. The committee reviewed safety data from the first dose cohort and found no significant concerns, allowing for the progression to enrollment of the second dose cohort. AMT-162 is an investigational gene therapy that may slow or halt the progression of ALS caused by SOD1 mutations. The company plans to begin this next phase of the trial in Q1 2025.
Read more →QURE▼ -9.8%on this news· ran to -25% by day 3
uniQure Announces Pricing of its Public Offering Lexington, MA and Amsterdam, the Netherlands
uniQure N.V. has announced the pricing of its public offering of 4,411,764 ordinary shares at $17.00 per share, targeting approximately $75 million in gross proceeds. The offering is expected to close around January 10, 2025, subject to customary closing conditions. The company has a significant gene therapy portfolio, including treatments for hemophilia B and other severe diseases. The communication emphasizes the advancements in their therapies while also noting standard forward-looking statements.
Read more →QURE▼ -9.8%on this news· ran to -25% by day 3
uniQure Announces Pricing of its Public Offering
uniQure N.V. announced the pricing of its public offering of 4,411,764 ordinary shares at $17.00 per share, aiming to raise approximately $75 million before expenses. The offering is managed by several bookrunning and lead managers and is expected to close around January 10, 2025, contingent on customary closing conditions. This funding will support uniQure's pipeline of gene therapies targeting various severe diseases, building on its success with hemophilia B.
Read more →QUREuniQure Announces Proposed Public Offering
uniQure N.V. has announced a proposed public offering of its ordinary shares and pre-funded warrants. The offering will be underwritten and is subject to market conditions. UniQure aims to grant underwriters a 30-day option to purchase up to 15% more shares at the public offering price. The company's current pipeline focuses on gene therapies for severe conditions, building on its previous successes in the field.
Read more →QURE▲ +109.7%on this news
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared
uniQure has announced a significant alignment with the FDA regarding the Accelerated Approval pathway for AMT-130, a gene therapy for Huntington's disease. The FDA has agreed that data from ongoing Phase I/II studies can serve as the primary basis for a Biologics License Application (BLA) and that the composite Unified Huntington's Disease Rating Scale may be used as an intermediate clinical endpoint. This milestone is expected to expedite the provision of potentially life-changing therapies for patients suffering from this neurodegenerative disorder. uniQure will engage further with the FDA in early 2025 to finalize the development plan.
Read more →QUREuniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy Lexington, MA and Amsterdam, the Netherlands
uniQure has announced the dosing of the first patient in its GenTLE Phase I/IIa clinical trial of AMT-260 for refractory mesial temporal lobe epilepsy (MTLE). This trial aims to evaluate the safety and efficacy of AMT-260, which is designed to reduce seizure frequency in patients unresponsive to current treatments. The trial will involve two cohorts of six patients and is actively recruiting across multiple sites in the U.S. This milestone is part of uniQure's broader efforts to advance gene therapies for serious conditions.
Read more →QURE▲ +9%on this news· ran to +40% by day 3
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited
uniQure N.V. reported its third quarter 2024 financial results, highlighting recent clinical advancements and financial strategies. The company announced a Type B meeting with the FDA aimed at discussing an expedited pathway for its gene therapy AMT-130 for Huntington's disease. Positive interim data from the ongoing Phase I/II trial showed promise in slowing disease progression. Financially, uniQure maintained a strong cash position while implementing a strategic restructuring to reduce expenses, though it reported a significant net loss for the quarter.
Read more →QUREuniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS Lexington, MA and Amsterdam, the Netherlands
uniQure has initiated its Phase I/II clinical trial for AMT-162, targeting SOD1-ALS by dosing its first patient. This investigational gene therapy aims to provide a novel treatment approach through one-time, intrathecal administration. The trial will assess safety, tolerability, and exploratory signs of efficacy by measuring biomarkers related to neuronal damage. With positive regulatory designations and a focus on generating proof-of-concept data, this marks a significant step in addressing the medical needs of SOD1-ALS patients.
Read more →QURE▼ -5.8%on this news
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease Lexington, MA and Amsterdam, the Netherlands, September, 23, 2024 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy comp
uniQure N.V. has announced that the FDA granted Orphan Drug Designation to their investigational gene therapy AMT-191 for the treatment of Fabry disease. This designation underscores the necessity for new treatments, especially considering the limited efficacy of current therapies. The company is currently conducting a Phase I/IIa trial in the U.S. to assess the safety and early efficacy of AMT-191. The trial's results are anticipated to provide initial clinical data by 2025.
Read more →QUREuniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease Lexington, MA and Amsterdam, the Netherlands, August, 15, 2024 - uniQure N.V. (NASDAQ: QURE), a leadin
uniQure N.V. has announced the dosing of the first patient in a Phase I/IIa clinical trial for AMT-191, aimed at treating Fabry disease. This multi-center, open-label study will assess the safety and early efficacy of AMT-191, utilizing AAV delivery technology. Company executives highlighted their commitment to advancing multiple gene therapy candidates this year, amidst the challenges of clinical development and regulatory scrutiny. The trial's outcomes will be pivotal in determining the future of AMT-191 and its potential as a treatment option for Fabry disease.
Read more →QUREuniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disea
uniQure N.V. reported its financial results for Q2 2024, highlighting significant progress with the RMAT designation for AMT-130 aimed at Huntington's disease and promising interim clinical trial data. The company initiated patient screenings for three additional Phase I/II studies across various conditions. Notably, uniQure is undergoing an organizational restructuring to streamline operations, which will result in a substantial reduction in workforce and operational costs. Despite a stronger cash position, the company reported a net loss of $56.3 million, raising concerns over increased non-operating expenses.
Read more →QURE▲ +5.4%on this news
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immedia
uniQure has finalized the sale of its Lexington, Massachusetts manufacturing facility to Genezen, a contract development and manufacturing organization. This transaction is expected to reduce uniQure's annual cash burn by around $40 million and streamline its operations. The agreement allows uniQure to maintain preferential access to leading gene therapy manufacturing capabilities, supporting the company's pipeline. This strategic move is geared towards enhancing shareholder value through focused investments in key projects.
Read more →QURE▲ +76.5%on this news· ran to +168% by day 1
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease ~ Achieved statistically significant, dose-dependent, and durable evide
uniQure reported promising interim data from Phase I/II trials of AMT-130 for Huntington's disease, showcasing an 80% reduction in disease progression over 24 months. The treatment also led to a statistically significant decrease in CSF neurofilament light protein levels. Additionally, AMT-130 has been granted RMAT designation by the FDA, highlighting its potential for expedited clinical development. The company plans to meet with the FDA later in 2024 to discuss further steps in the clinical development process.
Read more →QUREuniQure Announces Sale of Commercial Manufacturing Facility to Genezen ~ Proposed divestiture streamlines uniQure's focus and represents an important milestone in its ongoing effort to significantly reduce operating expe
uniQure N.V. has announced the sale of its commercial manufacturing facility in Lexington, Massachusetts to Genezen for $25 million. This strategic divestiture is aimed at significantly reducing operating expenses, with an expected annual cash burn reduction of approximately $40 million. Following the transaction, Genezen will manufacture the global commercial supply of HEMGENIX and will support uniQure's pipeline programs. The deal reflects uniQure's ongoing efforts to streamline operations and enhance financial flexibility.
Read more →QURE▲ +7.7%on this news
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease ~ Designation based on 24-month interim Phase I/II clinical data for AMT-130
uniQure N.V. has announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy AMT-130, which targets Huntington's disease. This designation was based on the analysis of 24-month interim clinical data showing the therapy’s potential to meet significant unmet medical needs. The RMAT designation enables enhanced collaboration with the FDA, allowing for expedited development and approval processes. Expectations are set for an update on interim Phase I/II clinical data in mid-2024.
Read more →QUREuniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress ~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phas
uniQure N.V. (NASDAQ: QURE) announced its financial results for Q1 2024, highlighting significant progress in its clinical trials and FDA interactions. The company is set to initiate discussions with the FDA regarding AMT-130 in the second quarter of 2024 and has begun preparations for three new Phase I/II trials targeting Fabry disease, refractory mesial temporal lobe epilepsy, and SOD1-ALS. While revenues increased to $8.5 million, the company reported a net loss of $65.6 million, raising concerns on financial sustainability amidst a comprehensive review of operations.
Read more →QUREuniQure Announces 2023 Financial Results and Highlights Recent Company Progress ~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of foll
uniQure N.V. reported its 2023 financial results and highlighted substantial progress in its clinical programs, including promising updates from Phase I/II trials of its gene therapy AMT-130 for Huntington's disease. The company received FDA clearance for two Investigational New Drug applications, with new trials set to begin in 2024. Despite a large net loss of $308.5 million, uniQure maintains a strong cash position of approximately $618 million, expected to support operations well into 2027. The company is focused on regulatory interactions to clarify approval pathways and advance its clinical programs efficiently.
Read more →QURE▼ -16.8%on this news
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease ~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with p
uniQure N.V. has provided an update on the Phase I/II clinical trials of AMT-130, a gene therapy for Huntington's disease. The interim data shows promising results, with patients treated exhibiting preserved neurological function and positive trends in various clinical measures. The treatment appears to be generally well-tolerated, although some serious adverse events were reported. Ongoing monitoring and discussions for regulatory strategies are planned as the trial continues.
Read more →QUREuniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure N.V. has announced the grant of inducement equity awards to 28 newly hired employees, as part of their strategy to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include 142,300 restricted share units and options to purchase 52,500 ordinary shares, with vesting terms designed to incentivize long-term commitment. This move reflects uniQure's ongoing expansion and commitment to advancing its gene therapy pipeline, including therapies for severe conditions such as hemophilia B.
Read more →QUREuniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
uniQure N.V. announced FDA clearance of its Investigational New Drug (IND) application for AMT-191, a gene therapy targeting Fabry disease. This therapy utilizes an AAV5 vector to deliver a GLA transgene aimed at producing the deficient protein in the liver. The Phase I/II clinical trial will assess the safety and efficacy of the treatment and is set to enroll participants in the first half of 2024. This development represents a key advancement in uniQure’s pipeline, which aims to address various severe genetic disorders.
Read more →QURE▲ +12.7%on this news
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress ~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epileps
uniQure N.V. announced its financial results for the third quarter of 2023, highlighting key developments including FDA clearance for the AMT-260 IND in refractory mesial temporal lobe epilepsy. The company reported a cash and investment position of approximately $660 million. Although revenues remained unchanged at $1.4 million, the company faced increased research and development expenses and a significant net loss compared to the prior year. Future plans include initiating patient enrollment for several clinical trials, with updates expected in the upcoming months.
Read more →QUREuniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
uniQure N.V. is presenting significant data at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting from October 24-27, highlighting their expertise in gene therapy manufacturing and research. Key presentations include updates on clinical trials for Huntington's disease and ALS, among others. This participation underscores uniQure's commitment to advancing critical therapies for severe medical conditions and builds on their recent success with hemophilia B treatments.
Read more →QURE▲ +11.6%on this news
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs ~ Reduction of 28% of workforce not related to HEMGENIX manufacturing obligations; Total
uniQure N.V. has announced a strategic reorganization aimed at reducing operating expenses and advancing its clinical-stage programs. This involves a 28% workforce reduction and discontinuation of more than half of its research projects, while prioritizing initiatives with the highest potential value. The company is expected to achieve around $180 million in cost savings, which would extend its cash runway. Key leadership changes accompany these shifts, with Dr. Rich Porter taking over research responsibilities. The restructuring aims to help accelerate the development of promising therapies for severe medical conditions.
Read more →QURE▼ -9.9%on this news
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
uniQure N.V. announced that the FDA has cleared its Investigational New Drug application for AMT-260, a gene therapy aimed at treating refractory mesial temporal lobe epilepsy (MTLE). This therapy utilizes an AAV9 vector to deliver engineered miRNAs to suppress the GRIK2 gene, which is believed to cause seizures. The upcoming Phase I/IIa clinical trial will evaluate the therapy's safety, efficacy, and tolerability, with patient screening expected to begin in Q4 2023. This marks a significant advancement in treatment options for patients with a high unmet medical need.
Read more →QUREuniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress ~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington's disease showi
uniQure N.V. has announced its financial results for the second quarter of 2023, reporting a net loss of $68.5 million, which is higher than the previous year. The company highlighted promising interim results from its ongoing Phase I/II trial of AMT-130 for Huntington's disease, demonstrating preserved clinical function in patients. With a strong cash position, uniQure is also preparing to initiate new clinical trials in refractory temporal lobe epilepsy and SOD1-ALS later this year. The recent appointment of key officers aims to enhance its strategic direction for future therapies.
Read more →QUREuniQure Announces Leadership Addition to Support Advancement of Clinical Programs
uniQure N.V. has appointed Dr. Walid Abi-Saab as its new Chief Medical Officer to strengthen its clinical development team. Dr. Abi-Saab, previously Chief Medical Officer at Galapagos, brings over two decades of experience in biopharma and will oversee clinical research and program management. His appointment aligns with uniQure's efforts to advance its gene therapy programs, particularly AMT-130 for Huntington's disease. The announcement also includes Dr. Ricardo Dolmetsch being promoted to President and Chief Scientific Officer.
Read more →QURE▼ -40.2%on this newsshared move
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
uniQure reported positive interim results from its U.S. Phase I/II clinical trial of AMT-130 for Huntington's disease, with data showing that patients experienced preserved function and favorable clinical metrics. After up to 24 months of follow-up on 26 patients, treatment demonstrated evidence of safety and promising efficacy, leading the company to continue with clinical development and regulatory discussions. The results indicate a potential benefit for patients, encouraging further investigation into AMT-130 as a potential therapy.
Read more →QUREuniQure announces achievement of $100 million milestone related to hemophilia B gene therapy ~ Milestone payment triggered by first commercial sale of HEMGENIX in U.S. by CSL Behring ~ Lexington, MA and Amsterdam, the Ne
uniQure N.V. has announced the achievement of a $100 million milestone tied to the first commercial sale of its gene therapy HEMGENIX in the U.S., conducted by CSL Behring. HEMGENIX is the first approved gene therapy for hemophilia B in the U.S. and European markets, promising to significantly improve patient outcomes. The milestone showcases uniQure's success in advancing its gene therapy technology and marks a notable achievement in genomic medicine. This milestone payment is expected to bolster uniQure's pipeline and ongoing collaborations.
Read more →QUREuniQure Announces Sale of Royalty Interest in HEMGENIX for Up To $400 Million ~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future
uniQure N.V. has announced a definitive agreement to sell a portion of its royalty rights from CSL Behring related to HEMGENIX for a total of up to $400 million. The transaction provides uniQure with an upfront payment of $375 million and allows for additional milestone payments up to $25 million based on future sales performance. This deal is expected to extend uniQure's cash runway until the second quarter of 2026 and is seen as a validation of the therapeutic's commercial potential. UniQure will continue to retain rights to significant future royalties and milestone payments under its license agreement with CSL Behring.
Read more →QUREuniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress ~ Clinical update from U.S. Phase I/II trial in Huntington's disease expected in second quarter 2023 ~ ~ Continued progress to
uniQure N.V. reported its financial results for Q1 2023, highlighting a revenue increase to $5.3 million driven primarily by contract manufacturing of HEMGENIX. The company is making strides in its clinical development, particularly with AMT-130 in Huntington's disease, with updates expected in the coming quarter. They have initiated plans for two new clinical studies targeting refractory temporal lobe epilepsy and SOD1-ALS. Despite these advancements, uniQure faces challenges with a widening net loss and rising R&D expenses.
Read more →QUREuniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
uniQure N.V. will prominently showcase 12 data presentations at the ASGCT Annual Meeting in Los Angeles, focusing on cutting-edge advancements in gene therapy. Notable presentations include the development of AAV-based therapies for ALS and other neurological conditions. Ricardo Dolmetsch, the Head of Research, highlighted the significance of these presentations and the company’s ongoing commitment to advancing its gene therapy pipeline. Alongside its innovative research, uniQure emphasizes its leadership in AAV gene therapy manufacturing.
Read more →QUREuniQure to Participate in Multiple Upcoming Industry Conferences in March
uniQure N.V. announced its participation in several industry conferences throughout March 2023, highlighting key management engagements. CEO Matt Kapusta will join investor meetings and participate in a corporate panel discussion at the Cowen Annual Healthcare Conference. Other events include presentations at the Bioprocessing Summit Europe and the Huntington's Disease Youth Organization Congress. The company's continued focus on gene therapy reflects its commitment to addressing severe medical conditions through innovative treatments.
Read more →QURE▲ +5.2%on this newsshared move
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress ~ Achieved U.S. and European Commission marketing approvals of first and only gene therapy for adults with hemophilia B ~ ~ Advancing develo
uniQure N.V. reported its 2022 financial results, highlighting significant achievements in gene therapy, including the marketing approvals for HEMGENIX, the first gene therapy for hemophilia B. The company also made advancements in its pipeline with upcoming treatments for Huntington's disease and efforts in refractory temporal lobe epilepsy and ALS. Despite a notable drop in revenue and a net loss for the year, uniQure's strong cash position and commitment to innovative therapies suggest potential for future growth.
Read more →QUREuniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX (etranacogene dezaparvovec-drlb)
uniQure announced the publication of HOPE-B clinical trial results in the New England Journal of Medicine, highlighting the effectiveness of HEMGENIX in treating adults with hemophilia B. The trial demonstrated that HEMGENIX significantly reduces annual bleeding rates and the need for factor IX prophylaxis therapy. The treatment was shown to maintain elevated factor IX levels for up to 18 months. The results reinforce the long-term efficacy and safety of HEMGENIX, marking a significant advancement in gene therapy for this condition.
Read more →QUREuniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B ~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment
uniQure has announced that the European Commission has approved HEMGENIX, the first gene therapy for adults with hemophilia B. This landmark approval marks a significant advancement in the treatment options available for patients, potentially allowing them to produce their own factor IX and significantly reducing their annual bleeding rates. The approval is based on findings from the pivotal HOPE-B trial, which demonstrated durable increases in Factor IX activity levels and greatly diminished the need for routine prophylactic therapy. The therapy is expected to improve the quality of life for patients while lessening the burden of ongoing treatments.
Read more →QUREuniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1 ~ License of APB-102 further strengthens uniQure's pipeline of innov
uniQure N.V. has entered into a global licensing agreement with Apic Bio for APB-102, a clinical stage gene therapy aimed at treating SOD1-linked amyotrophic lateral sclerosis (ALS). This agreement allows uniQure to develop and commercialize APB-102, adding to its growing pipeline of gene therapies for neurological disorders. The FDA has already approved the investigational new drug application for APB-102, which will be administered intrathecally and aims to slow down or potentially reverse ALS progression. A Phase I/II trial is planned for the second half of 2023.
Read more →QUREuniQure announces positive CHMP opinion for etranacogene dezaparvovec - gene therapy for adults with hemophilia B ~ If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people liv
uniQure announces positive CHMP opinion for etranacogene dezaparvovec - gene therapy for adults with hemophilia B ~ If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B ~ Lexington, MA and Amsterdam, the
Read more →QURE▼ -6%on this news
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therap
Read more →QURE▲ +7.1%on this news· ran to +27% by day 3
uniQure announces FDA approval of first gene therapy for adults with hemophilia B ~ Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylacti
uniQure announces FDA approval of first gene therapy for adults with hemophilia B ~ Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor
Read more →QUREuniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~ LEXINGTON, Ma. and AMSTERDAM, Nov. 17, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, tod
Read more →QURE▲ +7.3%on this news
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress ~ Patient enrollment at the higher dose of AMT-130 to resume in European Phase Ib/II study following Data Safety Monitoring Bo
Announces Third Quarter 2022 Financial Results Highlights Recent Company Progress Patient enrollment at the higher dose of AMT-130 to resume in European Phase Ib/II study following Data Safety Monitoring Board recommendation and European pre-approval inspections of Company's
Read more →QUREuniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations will be delivere
Read more →QUREuniQure to Participate in Upcoming Industry Conferences in October
LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scient
Read more →QURE▼ -5.6%on this news
uniQure to Participate in Upcoming Industry Conferences in September
LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scien
Read more →QURE▼ -27%on this news
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress ~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington's disease showed the investigative gene therapy w
Second Quarter 2022 Financial Results Recent Company Progress ~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington's disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant Hunting
Read more →QURE▲ +27%on this news
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with
Read more →QURE▲ +6.3%on this news
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review ~ If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with
FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review ~ If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B ~ Lexington, MA and Amsterdam, the Netherlands, May 24, 2022
Read more →QURE▲ +5.6%on this news
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, wi
Read more →QURE▲ +5.6%on this news
uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress ~ Partner CSL Behring submitted Marketing Authorization Application (MAA) in Europe for etranacogene dezaparvovec in hemophili
uniQure Announces First Quarter 2022 Financial and Highlights Recent Company Progress ~ Partner CSL Behring submitted Marketing Authorization Application (MAA) in Europe for etranacogene dezaparvovec in hemophilia B; MAA validated by the European Medicines Agency (EMA) and
Read more →QUREuniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease Lexington, MA and Amsterdam, the Netherlands
uniQure Announces Completion of Patient Enrollment First Two Cohorts of its Phase I/II Clinical for the Treatment of Huntington's Disease Lexington, MA and Amsterdam, the Netherlands, March 21, 2022 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing trans
Read more →QURE▲ +5.2%on this news
uniQure Announces 2021 Financial Results and Highlights Recent Company Progress ~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-months and statistical superiority in reduc
uniQure Announces 2021 Financial Results and Highlights Recent Company Progress ~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-months and statistical superiority in reducing annualized bleeding rate compared to baseline FIX pr
Read more →QUREuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease Lexington, MA and Amsterdam, the Netherlands
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease MA and Amsterdam, the Netherlands, February 7, 2022 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies
Read more →QURE▼ -29.6%on this news
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease ~ Treatment was well tolerated with no significant safety issues related
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease ~ Treatment was well tolerated with no significant safety issues related to AMT-130 in first two treated patients through one
Read more →QUREuniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B ~ Largest gene therapy study in hemophilia B achieved primary end
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B ~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate afte
Read more →QURE▲ +7.6%on this news
uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~ ~ Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company ad
Read more →QUREuniQure to Participate in Upcoming Industry Conferences in November
LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scient
Read more →QUREuniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress ~ Completed 78-week follow-up for hemophilia B pivotal study, with top-line data expected by year-end 2021 ~ ~ Enrolled 14 pat
uniQure Announces Third Quarter 2021 Financial and Highlights Recent Company Progress ~ Completed 78-week follow-up for hemophilia with top-line data expected by year-end 2021 ~ Enrolled 14 patients to date in Phase 1/2 clinical trial of AMT-130 in Huntington's Disease, with
Read more →QUREuniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors.
Read more →QUREuniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one or
Read more →QUREuniQure to Participate in Multiple Upcoming Industry Conferences in October
LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scien
Read more →QURE▲ +12.3%on this news
uniQure to Participate in Multiple Upcoming Industry Conferences in September
LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scien
Read more →QUREuniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~ ~ Full Study Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene th
Read more →QUREuniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress ~ Expanded gene therapy pipeline with four new research programs and announced acquisition of Corlieve Therapeutics ~ ~ Prese
uniQure Announces Second Quarter 2021 Financial and Highlights Recent Company Progress ~ Expanded gene therapy pipeline with four new research programs and announced acquisition ~ Presented positive 52-week data from HOPE-B pivotal study demonstrating sustained increases in
Read more →QUREuniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations, of which three
Read more →QUREuniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update
~ Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in full study population one year following a single administration of etranacogene dezaparvovec ~ ~ Held pre-BLA submission meeting with FDA and aligned on primary endpoint analysis
Read more →QUREuniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE) ~ Expands uniQure's Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~ ~ Strengthen
uniQure to Acquire Corlieve Therapeutics Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE) ~ Expands uniQure's Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~ ~ Strengthens uniQure's Global Leadership in the Development of Gene Therapies that
Read more →QUREuniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first two patient procedures have bee
Read more →QUREuniQure to Participate in Multiple Upcoming Industry Conferences in June
LEXINGTON, Mass. and AMSTERDAM, June 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor an
Read more →QUREuniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 27, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Boa
Read more →QUREuniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~ ~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients -- ~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual M
Read more →QUREuniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress ~ 52-week follow-up data from HOPE-B pivotal study expected to be presented later this quarter ~ ~ Announced closing of the gl
uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress ~ 52-week follow-up data from HOPE-B pivotal study expected to be presented later this quarter ~ closing of the global commercialization and license agreement with CSL Behring for he
Read more →QUREuniQure announces closing of commercialization and license agreement with CSL Behring ~Upfront payment of $450 million due to uniQure by
uniQure announces closing of commercialization and license agreement with CSL Behring ~Upfront payment of $450 million due to uniQure by May 13, 2021~ Lexington, MA and Amsterdam, the Netherlands, May 6, 2021 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company adva
Read more →QUREuniQure to Participate in Multiple Upcoming Industry Conferences in May
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming vir
Read more →QUREuniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 28, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that five data presentations, of which two ar
Read more →QUREuniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program Lexington, MA and Amsterdam, the Netherlands
uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program Lexington, MA and Amsterdam, the Netherlands, April 26, 2021 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical need
Read more →QUREuniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain
LEXINGTON, Mass. and AMSTERDAM, April 08, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that three manuscripts on preclinical data from its gene thera
Read more →QUREuniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~ ~ Company announces plans to initiate a second clinical study of AMT-130 in Europe in the second half of 2021 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 05, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (N
Read more →QUREun iQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease ~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~ ~ Company an
Completion of Enrollment in First Cohort of Trial of AMT-130 for the Treatment of Huntington's Disease ~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~ ~ Company announces plans to initiate a second clinical study of AMT-130 in Europe in the second half of
Read more →QUREuniQure to Participate in Multiple Upcoming Industry Conferences in April
LEXINGTON, Mass. and AMSTERDAM, April 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor a
Read more →QUREuniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program
~ Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause of HCC in HOPE-B pivotal trial ~ ~ Data from investigation submitted to U.S Food and Drug Administration (FDA) on March 26, 2021 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherland
Read more →QUREuniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program ~ Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause of
uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program ~ Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause of HCC in HOPE-B pivotal trial ~ ~ Data from investigatio
Read more →QUREuniQure Announces 2020 Financial Results and Highlights Recent Company Progress ~ Six patient procedures now completed in Phase I/II for Huntington's disease, including two procedures conducted in February 2021, with ful
uniQure Announces 2020 Financial Results and Highlights Recent Company Progress procedures now completed in Phase I/II for Huntington's disease, including two procedures conducted in February 2021, with full enrollment of first cohort expected mid-2021 ~ in HOPE-B pivotal stu
Read more →QUREuniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
~ No Significant Safety Concerns Observed ~ ~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment ~ ~ Full Enrollment of First Cohort Expected Mid-2021 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 08, 2021 (GLOBE NEWSWIRE) -- uniQure
Read more →QUREuniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease ~ No Significant Safety Concerns Observed ~ ~ Independent Data
Announces Positive Recommendation from Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 the Treatment of Huntington's Disease ~ No Significant Safety Concerns Observed ~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment ~ ~
Read more →QUREuniQure to Participate in Multiple Upcoming Industry Conferences in February
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming vi
Read more →QUREuniQure Announces Clinical Update on Hemophilia B Gene Therapy Program ~ Company to hold conference call today at 8:30 a.m. ET ~ Lexington, MA and Amsterdam, the Netherlands
uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program ~ Company to hold conference call today MA and Amsterdam, the Netherlands, December 21, 2020 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients w
Read more →QUREuniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62 nd Annual Meeting of the American Society of Hematology ~ First primary
Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Dezaparvovec Gene Therapy in Patients with Hemophilia B at the Annual Meeting of the American Society of Hematology endpoint in study met with mean Factor IX activity of 37% of normal at 26 weeks ~ 91% reduction in
Read more →QUREuniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B ~ Sustained FIX Activity at Therapeutic Levels 1 with
Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B ~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etr
Read more →QUREuniQure to Participate in Multiple Upcoming Industry Conferences in December
LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its participation in the following upcoming virtual investo
Read more →QUREuniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
~ Strong Presence at ASH Featuring Five Presentations, Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday, December 8, 2020 at 5:00 p.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N
Read more →QUREuniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B ~ Phase III study in 54 patients met primary endpoint with mean Factor IX act
uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B ~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~ ~ Patients achieved
Read more →QUREuniQure to Participate in Multiple Upcoming Industry Conferences in November
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that members of uniQure’s management team incl
Read more →QUREuniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation a
Read more →QUREuniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress ~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease ~ ~ Top-Line Data from HOPE-B P
Announces Third Quarter 2020 Financial Results Highlights Recent Company Progress Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease ~ Top-Line Data from HOPE-B Pivotal Trial in Hemophilia B Expected Before Year End ~ Initiated IND-en
Read more →QUREuniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient procedures have been completed in t
Read more →QUREuniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) overs
Read more →QUREuniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development ~ Announces Planned Departure of Sander van Deventer and Transition of Robert Gut Who is Expected to Remain on the Board of
uniQure Announces Appointment of Ricardo as President, Research & Development ~ Announces Planned Departure of Sander van Deventer and Transition of Robert Gut Who is Expected to Remain on the Board of MA and Amsterdam, the Netherlands, August 26, 2020 - uniQure N.V. (NASDAQ
Read more →QUREuniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress ~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure's Gene Th
uniQure Announces Second Quarter 2020 and Highlights Recent Company Progress ~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure's Gene Therapy Candidate for Hemophilia B ~ ~ Completed First Patient Dosing in Pha
Read more →QUREuniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy ~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure's Differentiated Gene Therapy Candidate f
uniQure Announces License Agreement to Commercialize Hemophilia B Gene Therapy ~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure's Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,
Read more →QUREuniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease ~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington's Disease ~ Lexing
Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease ~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington's Disease ~ MA and Amsterdam, the Netherlands, June 19, 2020 - uniQure N.V. (NASDAQ
Read more →QUREuniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~ LEXINGTON, Mass. and AMSTERDAM, June 17, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
Read more →QUREuniQure Announces Change for its 2020 Annual General Meeting of Shareholders
~ Virtual Meeting Only by Live Audio Webcast – No Physical Meeting Location ~ LEXINGTON, Mass. and AMSTERDAM, June 15, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE) announced today a change to the location and format of its 2020 Annual General Meeting of Shareholders (the
Read more →QUREuniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting ~ Substantial Presence with 22 Data Presentations Highlighting Breadth of Research, Technology and Manufacturing
uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting ~ Substantial Presence with 22 Data Presentations Highlighting Breadth of Research, Technology and Manufacturing Platform ~ ~ New Non-Human Primate Data Demonstrate Fea
Read more →QUREuniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress ~ Completed Target Patient Dosing in Phase III HOPE-B Trial of E tranacogene Dezaparvovec in Hemophilia B ~ ~ Announced 22 Pre
uniQure Announces First Quarter 2020 and Highlights Recent Company Progress Target Patient Dosing in Phase III HOPE-B Trial of Etranacogene Dezaparvovec ~ Announced 22 Presentations at Upcoming ASGCT Virtual Annual Meeting ~ MA and Amsterdam, the Netherlands, April 29, 2020
Read more →QUREuniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, April 28, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 22 data presentations, of which five are oral presentatio
Read more →QUREuniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors
LEXINGTON, Mass. and AMSTERDAM, April 17, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the nomination of Leonard E. Post, Ph.D. to stand for election
Read more →QUREuniQure to Participate in Multiple Upcoming Investor Conferences in April
LEXINGTON, Mass. and AMSTERDAM, March 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming investor ev
Read more →QUREuniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B ~ Provides Update on Phase I/II Clinical Trial of AMT-130 in Huntington's Disease and
uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B ~ Provides Update on Phase I/II Clinical Trial of AMT-130 in Huntington's Disease and Response to MA and Amsterdam, the Netherlands, March 26,
Read more →QUREuniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters
~ Gen-X Will Work with uniQure During an Exclusivity Period to Identify Novel Promoters for uniQure’s Product Portfolio ~ ~ uniQure Receives Option to Acquire Gen-X Business for Use in Gene Therapy ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, March 02, 2020 (GLOBE NEWSWIR
Read more →QUREuniQure Announces 2019 Financial Results and Highlights Recent Company Progress ~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of E tranacogene Dezaparvovec in Hemophilia B ~ ~ First Patient Procedure in Pha
uniQure Announces 2019 Financial Results and Highlights Recent Company Progress Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovec ~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease Expected to Occur
Read more →QUREuniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference
~ Up to Two Years of Follow-up in Large Transgenic Huntington’s Disease Model Demonstrates Stable mHTT Protein Lowering ~ ~ Novel Preclinical Data Demonstrates Successful Lowering of Pathogenic Exon 1 Fragment ~ ~ Additional Data Demonstrates the Potential of MRS as Imaging Bio
Read more →QUREuniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that seven presentations, of which one is an o
Read more →QUREuniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 19, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced two publications of preclinical data fro
Read more →QUREuniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
~ Sustained FIX Activity at Therapeutic Levels1 Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Zero Bleeds and No Requirement for Immunosuppression in One Year Following Dosing with Etranacogene Dezaparvovec ~ ~ Long-ter
Read more →QUREuniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that six data presentations will be deli
Read more →QUREuniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy ~ Third uniQure U.S. Patent Covering the Treatment of Hemophilia B and Other
uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy ~ Third uniQure U.S. Patent Covering the Treatment of Hemophilia B and Other Bleeding Disorders using FIX-Padua in AAV Gene Therapy ~
Read more →QUREuniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced the publication of 26-week interim data
Read more →QUREuniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
~ Announced Completion of Full Patient Enrollment in HOPE-B Pivotal Study of Etranacogene Dezaparvovec ~ ~ Achieved Site Initiation and Began Patient Screening for Phase I/II Clinical Study of AMT-130 in Huntington’s Disease ~ ~Strong Balance Sheet with September 30, 2019 Cash
Read more →QUREuniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B Lexington, MA and Amsterdam, the Netherlands
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B MA and Amsterdam, the Netherlands, September 3, 2019 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transfo
Read more →QUREuniQure Announces Leadership Promotions and Executive Transition Lexington, MA and Amsterdam, the Netherlands
uniQure Announces Leadership Promotions and Executive Transition MA and Amsterdam, the Netherlands, August 20, 2019 - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pro
Read more →QUREuniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress ~ Presented 36 Weeks of Follow-up Data from Phase IIb Study of AMT-061 Demonstrating Sustained Increases in FIX Activity at up to 54% o
uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress ~ Presented 36 Weeks of Follow-up Data from Phase IIb Study of AMT-061 Demonstrating Sustained Increases in FIX Activity at up to 54% of Normal ~ ~ Continuing Patient Recruitment in HOPE-B Pivo
Read more →QUREuniQure to Participate in Multiple Upcoming Industry Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 26, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upco
Read more →QUREuniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B ~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 We
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B ~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 Weeks After Administration of AMT-061 in Phase IIb Study ~
Read more →QUREuniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 21, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that five data presentations, of which three a
Read more →QUREuniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington s Disease ~ Issued Patents in the U.S. and EU Cover RNA Construct Specifically Designed to Target Highly Toxi
uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington s Disease ~ Issued Patents in the U.S. and EU Cover RNA Construct Specifically Designed to Target Highly Toxic Exon1 Protein ~ Lexington, MA and Amsterdam, the Nether
Read more →QUREuniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B ~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Admin
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B ~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Administration ~ ~ None of the Patients Received Factor Infus
Read more →QUREuniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting ~ Data Show AMT-150 Able to Significantly Lower Mutant Ataxin-3 Protein in SC
uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting ~ Data Show AMT-150 Able to Significantly Lower Mutant Ataxin-3 Protein in SCA3 Disease Model ~ ~ Provides Further Support of Proof-of
Read more →QUREAnnual Report 2018 uniQure N.V. Amsterdam
Amsterdam, May 3, 2019 Page A Report of the Board of Directors 2 1 Introduction 2 2 Financial results 30 3 Risk factors 35 4 Governance and compliance 40 5 Statement of the Board of Directors 53 B Consolidated Financial Statements of uniQure N.V. for the year ended Decemb
Read more →QUREuniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22 nd ASGCT Annual Meeting Lexington, MA and Amsterdam, the Netherlands
uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting Lexington, MA and Amsterdam, the Netherlands, May 2, 2019 uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapie
Read more →QUREuniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress ~ Presented Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B Demonstrating Increases in FIX Activity
uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress ~ Presented Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B Demonstrating Increases in FIX Activity Sustained at up to 51% of Normal at 12 Weeks ~ Achieved IN
Read more →QUREuniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, of which three a
Read more →QUREuniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington s Disease ~ On Track to Treat First Patient in Phase I/II Study of AMT-130 in 2H19 ~ Lexington, Mass. and Amsterdam, th
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington s Disease ~ On Track to Treat First Patient in Phase I/II Study of AMT-130 in 2H19 ~ Lexington, Mass. and Amsterdam, the Netherlands, April 8, 2019 uniQure N.V. (NASDAQ: QURE),
Read more →QUREuniQure Announces 2018 Financial Results and Highlights Recent Company Progress ~ Initiated Dosing Phase of HOPE-B Pivotal Study of AMT-061 in Hemophilia B ~ ~ Reported Updated Clinical Data from Phase IIb Study of AMT-0
uniQure Announces 2018 Financial Results and Highlights Recent Company Progress ~ Initiated Dosing Phase of HOPE-B Pivotal Study of AMT-061 in Hemophilia B ~ ~ Reported Updated Clinical Data from Phase IIb Study of AMT-061 Demonstrating Sustained FIX Activity at up to 51% of No
Read more →QUREuniQure Presents New Preclinical Data on AMT-130 at the CHDI s 14 th Annual Huntington s Disease Therapeutics Conference ~ AMT-130 Shows Restoration of Brain Cell Function and Reversal of Neuropathology in Huntington s D
uniQure Presents New Preclinical Data on AMT-130 at the CHDI s 14th Annual Huntington s Disease Therapeutics Conference ~ AMT-130 Shows Restoration of Brain Cell Function and Reversal of Neuropathology in Huntington s Disease Mouse Model ~ Lexington, MA and Amsterdam, the Nethe
Read more →QUREuniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced two recent online publications of preclinical
Read more →QUREuniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B ~ Increases in FIX Activity Sustained at up to 51% of Normal, with Mean FIX of 38% of Normal at Twelve Weeks After Adm
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B ~ Increases in FIX Activity Sustained at up to 51% of Normal, with Mean FIX of 38% of Normal at Twelve Weeks After Administration ~ ~ None of the Patients Received Factor Infu
Read more →QUREuniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B ~ Full Patient Enrollment in Study Expected by Year-End 2019 ~ Lexington, MA and Amsterdam, the Netherlands
uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B ~ Full Patient Enrollment in Study Expected by Year-End 2019 ~ Lexington, MA and Amsterdam, the Netherlands, February 4, 2019 uniQure N.V. (NASDAQ: QURE), a leading gene th
Read more →QUREuniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington s Disease ~ AMT-130 Poised to Become First AAV Gene Therapy to Enter the Clinic for Huntington s Disease ~ ~ Lead Product
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington s Disease ~ AMT-130 Poised to Become First AAV Gene Therapy to Enter the Clinic for Huntington s Disease ~ ~ Lead Product Candidate from Company s Proprietary miQURE Gene Silencin
Read more →QUREuniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B Clinical Benefit of AMT-060 Maintained in All Patients Through up to Two and
uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B Clinical Benefit of AMT-060 Maintained in All Patients Through up to Two and a Half Years of Follow-up Second Dose Cohort Demonstrated
Read more →QUREuniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day ~ Unveils New AAV Gene Therapy Approaches to Hemophilia A, Fabry Disease and Spinocerebellar Ataxia Type 3 ~ ~ Introduces
uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day ~ Unveils New AAV Gene Therapy Approaches to Hemophilia A, Fabry Disease and Spinocerebellar Ataxia Type 3 ~ ~ Introduces miQURE Gene Silencing Platform with Applications Across
Read more →QUREuniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B ~ All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31% of Normal at
uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B ~ All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31% of Normal at Six Weeks After Administration ~ ~ None of the Patients Re
Read more →QUREuniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress Lexington, MA and Amsterdam, the Netherlands
uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress Lexington, MA and Amsterdam, the Netherlands, November 6, 2018 uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical n
Read more →QUREuniQure to Host Research & Development Day on Monday, November 19 in New York City
~ Event to be Webcast Live on Corporate Website ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, Nov. 05, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announ
Read more →QUREuniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies
~ New Data Presented at the European Society of Gene and Cell Therapy Annual Meeting Demonstrates up to 40 Times Higher Liver Expression with Optimized Promoter ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 18, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a le
Read more →QUREuniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
~ Commercial Capacity for AAV Gene Therapy Production Significantly Enhanced by Highly Scalable 500 Liter Reactors ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 17, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transfor
Read more →QUREuniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
~ New Data Further Demonstrating Leading Gene Therapy Manufacturing and Administration Capabilities ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 16, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies
Read more →QUREuniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
~ Third patient treated in Phase IIb study ~ ~ Topline data expected to be available before the end of 2018 ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative
Read more →QUREuniQure to Participate at Multiple Upcoming Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upco
Read more →QUREuniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 23, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has treated the first patient in
Read more →QUREuniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress ~ Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061 ~ First Patient Successfully Screened into Phase I
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress ~ Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061 ~ First Patient Successfully Screened into Phase IIb Dose-Confirmation Trial of AMT-061 ~ Robert Gut, M.D.,
Read more →QUREuniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has enrolled its first patient in
Read more →QUREuniQure Announces New Appointments to its Board of Directors LEXINGTON, Mass. and AMSTERDAM, The Netherlands
uniQure Announces New Appointments to its Board of Directors LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 13, 2018 (GLOBE NEWSWIRE) uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, toda
Read more →QUREuniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy
~ Newly Issued Patents in the U.S. and Canada Cover Methods of Treating Hemophilia B and Other Bleeding Disorders using FIX-Padua in AAV Gene Therapy ~ ~ Additional Issued Patent Covering Manufacturing Further Strengthens Intellectual Property Portfolio ~ LEXINGTON, Mass. and A
Read more →QUREuniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
-- New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 -- -- Data Suggest AAV5 Gene Therapies May be Viable Treatments for at Least 97% of Patients -- -- Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Chicago -- LEXI
Read more →QUREuniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
-- Preclinical Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Chicago -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 18, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative
Read more →QUREuniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 07, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington’s disease and congestive
Read more →QUREuniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress
~ Patient enrollment expected to begin ahead of schedule in dose-confirmation study for AMT-061 and pivotal study on track to commence in third quarter of 2018 ~ IND filing for AMT-130 in Huntington’s Disease expected in second half of 2018 ~ Industry Leaders Robert Gut and Dav
Read more →QUREAnnual Report 2017 uniQure N.V. Amsterdam
Amsterdam, April 30, 2018 Page A Report of the Board of Directors 2 1 Introduction 2 2 Financial results 27 3 Risk factors 33 4 Governance and compliance 37 5 Statement of the Board of Directors 49 B Consolidated Financial Statements of uniQure N.V. for the year ended Dec
Read more →QUREuniQure Announces to Present at Multiple Conferences in May
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 27, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be featured in multiple presentations at upcoming medical and scientific conferences in May. 2nd Annual Ge
Read more →QUREuniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting
~ Mutant Huntingtin Protein Reduced by a Median of 68% in the Deep Structures of the Brain and a Median of 47% in the Frontal Cortex at 6 Months in a Large Diseased Animal Model ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 25, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (N
Read more →QUREuniQure Announces 2017 Financial Results and Recent Company Progress ~ On Track to Begin Pivotal Study of AMT-061 in Hemophilia B in Q3 2018 ~ Submitted IND Amendment for AMT-061 Dose Confirmation Study, with Topline Dat
uniQure Announces 2017 Financial Results and Recent Company Progress ~ On Track to Begin Pivotal Study of AMT-061 in Hemophilia B in Q3 2018 ~ Submitted IND Amendment for AMT-061 Dose Confirmation Study, with Topline Data Expected by End of 2018 ~ Expects IND Submission for AM
Read more →QUREuniQure to Participate in Multiple Conferences in March
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be featured in multiple presentations at upcoming medical, scientific and investor conferences during March.
Read more →QUREuniQure to Participate in Multiple Conferences in February
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that members of company management or principal investigators will participate in upcoming business, medical and investor
Read more →QUREuniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntington’s disease
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 22, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that AMT-130, its proprietary gene therapy cand
Read more →QUREuniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value
~ Pivotal Trial in Hemophilia B on Track to Begin in Q3 2018, with Initial AMT-061 Clinical Data by Year End ~ ~ AMT-130 Expected to be First AAV-Based Gene Therapy for Huntington’s Disease to Enter Clinic ~ ~ Strong Cash Position Sufficient to Fund Company into 2020 ~ LEXINGT
Read more →QUREuniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 18, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the online publication in Blood of clinical dat
Read more →QUREuniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
– Clinical Benefit Maintained in All Patients, with Durable Increases in FIX Clotting Activity at Up to Two Years of Follow-Up – – Second Dose Cohort Demonstrated 89% Reduction in Spontaneous Bleeds, with No Confirmed Bleeds Reported in Last 12 Months – – AAV5-Based Gene Therap
Read more →QUREuniQure Added to NASDAQ Biotechnology Index
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 11, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company has been added to the NASDAQ B
Read more →QUREuniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting
Non-human primate study of AMT-061 utilizing FIX-Padua shows 6.5-fold increase in FIX clotting activity Data supports nonclinical comparability plan agreed upon with FDA LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 09, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QUR
Read more →QUREuniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced its company-sponsored clinical data prese
Read more →QUREuniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2
Read more →QUREuniQure Announces Multiple Company Presentations at Upcoming November Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced company presentations at the following conferen
Read more →QUREuniQure Announces Closing of its Public Offering Lexington, MA and Amsterdam, the Netherlands
uniQure Announces Closing of its Public Offering Lexington, MA and Amsterdam, the Netherlands, October 27, 2017 uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Hunt
Read more →QUREuniQure Announces Closing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 27, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington’s disease and congestive
Read more →QUREuniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 ~ AMT-060 with the FIX-Padua Modification (AMT-061) Demonstrates Substantial Increase in FIX Activity in Non-human
uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 ~ AMT-060 with the FIX-Padua Modification (AMT-061) Demonstrates Substantial Increase in FIX Activity in Non-human Primates ~ ~ Plans to Initiate Pivotal Study with Enhance
Read more →QUREuniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)
~ Issued Patent in the U.S. Covers Use of FIX-Padua in Gene Therapy ~ ~ Divisional patent applications filed to further strengthen Padua intellectual property position ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 19, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE
Read more →QUREuniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at the ESGCT 25th Anniversary Congress in Berlin
One-time Administration of AMT-130 Demonstrates Survival Benefit and Functional Improvement of Huntington’s Disease Symptoms in Preclinical Study IND-enabling Toxicology Study Initiated LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 18, 2017 (GLOBE NEWSWIRE) -- uniQure N
Read more →QUREuniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington’s disease
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 06, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that AMT-130, its proprietary gene therapy cand
Read more →QUREuniQure Announces Company Presentations at Upcoming October Conferences LEXINGTON, Mass. and AMSTERDAM, the Netherlands
uniQure Announces Company Presentations at Upcoming October Conferences LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 02, 2017 (GLOBE NEWSWIRE) uniQure N.V. (NASDAQ:QURE) a leading gene therapy company advancing transformative therapies for patients with severe medical n
Read more →QUREuniQure Announces Company Participation at Citi Healthcare Conference
LEXINGTON, Mass and AMSTERDAM, the Netherlands, Aug. 24, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in a gene therapy panel
Read more →QUREuniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress ~ Advancing Gene Therapy Programs in Hemophilia B and Huntington s Disease ~ ~ Provides Update on Research Collaboration with Bristol-My
uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress ~ Advancing Gene Therapy Programs in Hemophilia B and Huntington s Disease ~ ~ Provides Update on Research Collaboration with Bristol-Myers Squibb ~ ~ Makes New Appointments to Company Leadersh
Read more →QUREuniQure Announces Leadership Team Appointments and Nominations to its Board of Directors Scott McMillan Named Chief Operating Officer Sander van Deventer Named Chief Scientific Officer, General Manager, Amsterdam Christi
uniQure Announces Leadership Team Appointments and Nominations to its Board of Directors Scott McMillan Named Chief Operating Officer Sander van Deventer Named Chief Scientific Officer, General Manager, Amsterdam Christian Klemt Promoted to Chief Accounting Officer Jeremy Spr
Read more →QUREuniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 31, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has entered into an agreement with Chie
Read more →QUREuniQure Reaquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B ~ Company now owns full global rights to late-stage program with clinical proof-of-concept ~ Lexington, MA and Ams
uniQure Reaquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B ~ Company now owns full global rights to late-stage program with clinical proof-of-concept ~ Lexington, MA and Amsterdam, the Netherlands, July 31, 2017 uniQure N.V. (NASD
Read more →QUREuniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program
-- Commercial-Scale Batches of AMT-060 Successfully Produced in Accordance with Good Manufacturing Practices in Lexington, MA Facility -- -- Manufacturing Process to be Leveraged in Huntington’s Program, With Production Expected to Begin Before Year End -- LEXINGTON, Mass. and
Read more →QUREuniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 18, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy and AAV manufacturing, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent for a proprietary i
Read more →QUREuniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 11, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented new clinical data demonstrating that the presen
Read more →QUREuniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B Clinical Benefit Maintained in All Patients, with FIX Activity Persisting At Up To 18 Month
uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B Clinical Benefit Maintained in All Patients, with FIX Activity Persisting At Up To 18 Months of Follow-Up Second-dose Cohort Demonstrates Dose Respo
Read more →QUREuniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis (ISTH) Congress
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 23, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two abstracts have been accepted for prese
Read more →QUREuniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies
-- Study published in Molecular Therapy provides proof of concept of successful cross-administration of AAV5- and AAV1-based gene therapies -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 15, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy co
Read more →QUREuniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer Lexington, MA and Amsterdam, the Netherlands
uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer Lexington, MA and Amsterdam, the Netherlands, June 6, 2017 uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced the appointment of Steven L. Zelenkofske, D.O, as Chief Medica
Read more →QUREuniQure Announces Company Presentation at Jefferies Healthcare Conference
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will present a corporate overview and h
Read more →QUREuniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates
– Effective Transduction Achieved After Readministration of Gene Transfer – – Preclinical Data Presented Today at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Washington, D.C. – – Investor & Analyst Breakfast and Webcast Friday, May 12 at 7:00 a.m. EDT – L
Read more →QUREuniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates
-- Strong Dose-Dependent Transduction in All Animals Tested Regardless of the Level of Anti-AAV5 Antibodies at Pre-Administration -- -- Data Suggests AAV5 Gene Therapies May be Viable Treatments for Nearly All Patients -- -- Preclinical Data Presented Today at American Society
Read more →QUREuniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress Lexington, MA and Amsterdam, the Netherlands
uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress Lexington, MA and Amsterdam, the Netherlands, May 9, 2017 uniQure N.V. (NASDAQ: QURE, a leading gene therapy company developing transformative therapies for patients with severe medica
Read more →QUREuniQure Announces Company Presentations at Upcoming May Conferences
-- Investor breakfast event and webcast at ASGCT on Friday, May 12 at 7:00 a.m. EDT -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients wit
Read more →QUREuniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference
-- One-time Administration of AMT-130 Demonstrates for the First Time Efficacy in Large Animal Model -- Strong Dose-Dependent Reduction of Mutant Huntingtin Protein and Widespread Vector Distribution in Brain -- IND-enabling Toxicology Study to Commence in 2H 2017 -- LEXINGTON
Read more →QUREuniQure Receives European Medicines Agency Priority Medicines (PRIME) Designation for AMT-060 in Hemophilia B
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 25, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that AMT-060, its proprietary, investigational
Read more →QUREuniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe Marketing Authorization for Glybera to Expire on
uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe Marketing Authorization for Glybera to Expire on October 25, 2017 Company Maintains Focus on Core Programs in Hemophilia B, Huntington s Disease and Congestive Heart Failure Lexington, M
Read more →QUREAnnual Report 2016 uniQure N.V. Amsterdam
Amsterdam, April 14, 2017 Page A Report of the Board of Directors 2 1 Introduction 2 2 Financial results 22 3 Risk factors 27 4 Governance and compliance 31 5 Statement of the Board of Directors 42 B Consolidated Financial Statements uniQure N.V. for the ye
Read more →QUREuniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 04, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the online publication in Gene Therapy of data
Read more →QUREuniQure Announces Presentations at Upcoming April Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced presentations at the following conferences tak
Read more →QUREuniQure Announces 2016 Financial Results and Provides Update on Company Progress LEXINGTON, Mass. and AMSTERDAM, the Netherlands
uniQure Announces 2016 Financial Results and Provides Update on Company Progress LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 15, 2017 (GLOBE NEWSWIRE) uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with seve
Read more →QUREuniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
-- Lexington, MA-based Gene Therapy Facility Recognized for Enabling Manufacturing Excellence -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it has been recog
Read more →QUREuniQure Announces Presentations at Upcoming March Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced presentations at the following conferences tak
Read more →QUREuniQure Announces Presentations at Upcoming February Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 06, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced presentations at the following conferences taking place in February: Leerink Partners 6th Annual Global Healthcare Confe
Read more →QUREuniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B LEXINGTON, Mass. and AMSTERDAM, the Netherlands
uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2017 (GLOBE NEWSWIRE) uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that AMT-060, its proprietary, investiga
Read more →QUREuniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 25, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Alexander Kuta, Ph.D., as Senior Vice President of Regulatory Affairs. Dr. Kuta has more than 25 years
Read more →QUREuniQure Outlines Key Initiatives for 2017 and Vision for 2018
-- Preparations Underway for Late-Stage Development in Hemophilia B -- Three Clinical-Stage Programs by 2018 Including One Pivotal and Two Proof-of-Concept Studies -- Company Strengthened Following Strategic Review and New Executive Leadership LEXINGTON, Mass. and AMSTERDAM, t
Read more →QUREuniQure Appoints Matthew Kapusta as Chief Executive Officer Lexington, MA and Amsterdam, the Netherlands
uniQure Appoints Matthew Kapusta as Chief Executive Officer Lexington, MA and Amsterdam, the Netherlands, December 19, 2016 uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its Board of Directors has unanimously approved the appointment of Matth
Read more →QUREuniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B Second-dose Cohort Demonstrates Dose Response with All Patients Free of Prophylact
uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B Second-dose Cohort Demonstrates Dose Response with All Patients Free of Prophylactic FIX Replacement Therapy and Only One Spontaneous Bleed R
Read more →QUREuniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
-- Second-dose Cohort Demonstrates Dose Response with All Patients Free of Prophylactic FIX Replacement Therapy and Only One Spontaneous Bleed Reported -- Low-Dose Cohort Shows Sustained Levels of FIX Activity Up To One Year, with Marked Reduction of Bleeding Over Time and a Com
Read more →QUREuniQure to Present at the Genetic Rx Boston Biotech Conference at Harvard Medical School
Amsterdam, The Netherlands, Dec. 02, 2016 (GLOBE NEWSWIRE) -- Lexington, MA and Amsterdam, the Netherlands, December 2, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced its participation in two panel discussions at the 2016 Genetic Rx Conference
Read more →QUREuniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress ~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Update
uniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress ~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Updated Clinical Data on AMT-060 in Hemophilia B at Upcoming A
Read more →QUREuniQure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington, MA ~Preparation
uniQure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington, MA ~Preparation Underway for Late-Stage Development in Hemophilia B ~Cost
Read more →QUREuniQure Announces Upcoming Presentation of Data at Annual American Society of Hematology Meeting
– Poster presentation on Saturday, December 3, 2016 – – Investor breakfast event on Monday, December 5 at 7:00 am PST/10:00 am EST – LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 03, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, t
Read more →QUREuniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 26, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that Matt Kapusta, interim chief executive officer, will present an overview of the company's programs and progress at
Read more →QUREuniQure Announces Management and Board Changes Lexington, MA and Amsterdam, the Netherlands
uniQure Announces Management and Board Changes Lexington, MA and Amsterdam, the Netherlands, September 22, 2016 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its Board of Directors has accepted the resignation of Daniel Soland as chief executi
Read more →QUREuniQure Announces Management and Board Changes
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its Board of Directors has accepted the resignation of Daniel Soland as chief executive officer (CEO) and an execu
Read more →QUREuniQure Receives NASDAQ Deficiency Letter Related to Board Composition Lexington, MA and Amsterdam, the Netherlands
uniQure Receives NASDAQ Deficiency Letter Related to Board Composition Lexington, MA and Amsterdam, the Netherlands, September 16, 2016 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it has received a letter from NASDAQ dated September 12, 2016
Read more →QUREuniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress ~ Progress Across the Pipeline ~ Additional data on AMT-060 in Hemophilia B Expected Later this Year ~Data from Sanfilippo B and
uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress ~ Progress Across the Pipeline ~ Additional data on AMT-060 in Hemophilia B Expected Later this Year ~Data from Sanfilippo B and Parkinson s Disease Studies Expected in Q1 2017 ~Strong
Read more →QUREuniQure to Present at Upcoming Investor Conferences in September
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 17, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that members of its leadership team will present an overview of the company's programs and progress at several upcoming
Read more →QUREuniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect Data from Low-Dose Cohort of AMT-060 Clinical Tria
uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect Data from Low-Dose Cohort of AMT-060 Clinical Trial Continues to Show Durability and Therapeutically Relevant
Read more →QUREuniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress
AMSTERDAM, The Netherlands, July 11, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that updated data from its ongoing Phase I/II clinical study of AMT-060 in hemophilia B patients will be presented at the World Federation of
Read more →QUREuniQure Appoints Jonathan Garen as Chief Business Officer
AMSTERDAM, the Netherlands, July 7, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Jonathan Garen as Chief Business Officer. Mr. Garen has more than 20 years of experience in business development within the
Read more →QUREuniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications
AMSTERDAM, the Netherlands, June 27, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Maria E. Cantor as Senior Vice President, Investor Relations and Communications. Ms. Cantor joins the Company from ARIAD Ph
Read more →QUREuniQure Presents Clinical Data from Ongoing Phase I/II Study in Hemophilia B Demonstrating 6 Months of Sustained Increases in Factor IX Activity
--Data from Low-Dose Cohort Presented at the 21st Congress of the European Hematology Association Show Durable and Therapeutically Relevant Factor IX (FIX) Expression-- --Median FIX Activity for All Five Patients in Low-Dose Cohort of 5.4%-- --Conference Call to Discuss Data Sc
Read more →QUREuniQure Announces Results for First Quarter 2016 Amsterdam, the Netherlands
uniQure Announces Results for First Quarter 2016 Amsterdam, the Netherlands, May 31, 2016 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2016, and provided a corporate update. We are very ple
Read more →QUREuniQure Announces Results for First Quarter 2016
AMSTERDAM, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2016, and provided a corporate update. "We are very pleased with our progress so far
Read more →QUREuniQure Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in Hemophilia B at the 21st Congress of the European Hematology Association
- Presentation to Include Most Recent Clinical Data from the Five Patient, Low-dose Cohort - - Company to Host Conference Call on Monday, June 13, 2016 at 2:00 pm CET/ 8:00 am EDT - AMSTERDAM, the Netherlands, May 19, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leade
Read more →QUREuniQure to Present at Upcoming Investor Conferences in New York City
AMSTERDAM, the Netherlands, May 12, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its management will be presenting at the below listed investor conferences in May and June, 2016. Piper Jaffray GenomeRx Symposium Venu
Read more →QUREuniQure Announces the Nomination of Jack Kaye to its Board of Directors and Proposed Corporate Governance Changes
AMSTERDAM, The Netherlands, May 9, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the nomination of Jack Kaye to stand for election to uniQure's Board of Directors. Mr. Kaye, who will also chair the Company's Audit Committee,
Read more →QUREAnnual Report 2015 uniQure N.V. Amsterdam
Amsterdam, May 2, 2015 Page A Management Report 2 1 Introduction 2 2 2015 highlights 5 3 Risk factors 20 4 Additional information 24 5 Director s statement 24 B Governance and compliance 25 1 Report by the Supervisory Board 25 2 Conformity Statement 31 C Corporate Gover
Read more →QURENotice to Convene the Annual General Meeting of Shareholders of uniQure N.V. To be held at and organized by uniQure N.V. (the Company ), having its address at Meibergdreef 61, 1105 BA Amsterdam, the Netherlands, at 2.00
Notice to Convene the Annual General Meeting of Shareholders To be held at and organized by uniQure N.V. (the Company ), having its address at Meibergdreef 61, 1105 BA Amsterdam, the Netherlands, at 2.00 p.m. CET on 15 June 2016. Shareholders are invited to attend the Annual Ge
Read more →QUREuniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT Amsterdam, the Netherlands
uniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT Amsterdam, the Netherlands, May 9, 2016 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical rese
Read more →QUREuniQure Appoints Paul Firuta as Chief Commercial Officer
AMSTERDAM, the Netherlands, May 3, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Paul Firuta as Chief Commercial Officer. Mr. Firuta, who held similar positions at NPS Pharmaceuticals, Inc. and ViroPharma,
Read more →QUREuniQure To Present Data On Gene Therapy Technology Advances At Annual Meeting Of The American Society Of Gene And Cell Therapy
AMSTERDAM, The Netherlands, April 19, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that six abstracts have been accepted for poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting h
Read more →QUREuniQure Announces Results for Fourth Quarter and Financial Year 2015 Amsterdam, the Netherlands
uniQure Announces Results for Fourth Quarter and Financial Year 2015 Amsterdam, the Netherlands, April 4, 2016 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced audited results for the fourth quarter and year ending December 31, 2015, and provided a co
Read more →QUREuniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington's Disease
AMSTERDAM, the Netherlands, March 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its proprietary Huntington's disease gene therapy program, AMT-130. Findings published in the
Read more →QUREuniQure Announces Dosing of First Patient in High-Dose Cohort in Phase I/II Hemophilia B Clinical Trial
AMSTERDAM, the Netherlands, March 14, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has treated the first patient in the second cohort of its ongoing AMT-060-01 Phase I/II trial in hemophilia B patients. The
Read more →QUREuniQure to Present at the 36th Cowen & Company Health Care Conference
AMSTERDAM, the Netherlands, March 2, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that its management will present at the 36th Cowen & Company Healthcare Conference to be held on March 7 - 9, 2016 at the Boston Marriott Copl
Read more →QUREuniQure to Present at the RBC Capital Markets 2016 Global Healthcare Conference
AMSTERDAM, the Netherlands, Feb. 15, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that Dan Soland, Chief Executive Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference on February 24, 2016 at 2:
Read more →QUREuniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial Meaningful Factor IX Expression Validates Successful Transduction of the Liver Using uniQure s Pro
uniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial Meaningful Factor IX Expression Validates Successful Transduction of the Liver Using uniQure s Proprietary AAV5 Vector Four of Five Patients Have Fully Disc
Read more →QUREuniQure Announces Conference Call and Webcast to Discuss Topline Results From Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
AMSTERDAM, the Netherlands, Jan. 6, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press rele
Read more →QUREuniQure Appoints Dan Soland as Chief Executive Officer
AMSTERDAM, the Netherlands, Dec. 18, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Dan Soland as the new Chief Executive Officer of the Company. Mr. Soland will succeed J rn Aldag, who has decided to step d
Read more →QUREuniQure Appoints Dan Soland as Chief Executive Officer Amsterdam, the Netherlands
uniQure Appoints Dan Soland as Chief Executive Officer Amsterdam, the Netherlands, December 18, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the appointment of Dan Soland as the new Chief Executive Officer of the Company. Mr. Soland will succ
Read more →QUREuniQure Announces Financial Results for Third Quarter 2015 and Provides Update on Product Pipeline and Company Development Conference call today, at 8:30am ET (1:30pm GMT/2:30pm CET) Amsterdam, the Netherlands
uniQure Announces Financial Results for Third Quarter 2015 and Provides Update on Product Pipeline and Company Development Conference call today, at 8:30am ET (1:30pm GMT/2:30pm CET) Amsterdam, the Netherlands, November 30, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human ge
Read more →QUREuniQure Announces Conference Call and Webcast to Discuss Third Quarter Financial Results and Corporate Update
AMSTERDAM, the Netherlands, Nov. 23, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release its financial results and a corporate update for the third quarter on November 30, 2015. uniQure management will
Read more →QUREuniQure to Present at the Jefferies 2015 Global Healthcare Conference - London
AMSTERDAM, the Netherlands, Nov. 12, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that its management will present at the Jefferies 2015 Global Healthcare Conference - London, to be held November 18-19, 2015. Date: November
Read more →QUREuniQure to Host Investor Day in New York City on October 15, 2015
AMSTERDAM, the Netherlands, Oct. 7, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be hosting an Investor Day and simultaneous webcast in New York City on October 15, 2015, starting at 8:30 a.m. uniQure management
Read more →QUREPositive Topline Results Announced from Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure s Novel AAV5-Based Gene Therapy Safety, Durable NaGlu Protein Expression and Positive Signs o
Positive Topline Results Announced from Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure s Novel AAV5-Based Gene Therapy Safety, Durable NaGlu Protein Expression and Positive Signs of Efficacy Demonstrated in All Four Patients First Clinical Validation of AAV5 V
Read more →QUREuniQure to Present at NewsMakers in the Biotech Industry Conference - NYC
AMSTERDAM, Netherlands, Sept. 1, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present at the NewsMakers in the Biotech Industry Conference, to be held September 10, 2015, at the Millennium Broadway
Read more →QUREuniQure Announces Financial Results for Second Quarter 2015 Amsterdam, the Netherlands
uniQure Announces Financial Results for Second Quarter 2015 Amsterdam, the Netherlands, August 27, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the second quarter and six months ending June 30, 2015, and provided an upda
Read more →QUREuniQure Announces Receipt of $53 Million From Bristol-Myers Squibb for Target Selection Payment and Additional Equity Investment
AMSTERDAM, the Netherlands, Aug. 10, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the receipt of an additional $53 million from Bristol-Myers Squibb in accordance with the companies' strategic collaboration to develop gene t
Read more →QUREuniQure Announces Receipt of $53 Million from Bristol-Myers Squibb for Target Selection Payment and Additional Equity Investment Amsterdam, the Netherlands
uniQure Announces Receipt of $53 Million from Bristol-Myers Squibb for Target Selection Payment and Additional Equity Investment Amsterdam, the Netherlands, August 10, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the receipt of an additional
Read more →QUREuniQure Announces Financial Results for First Quarter 2015 Amsterdam, the Netherlands
uniQure Announces Financial Results for First Quarter 2015 Amsterdam, the Netherlands, June 11, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2015, and provided an update on multiple gen
Read more →QUREuniQure Announces Financial Results for First Quarter 2015
AMSTERDAM, The Netherlands, June 11, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2015, and provided an update on multiple gene therapy programs. Hemophilia B: The Co
Read more →QUREuniQure to Present at the Jefferies 2015 Healthcare Conference
AMSTERDAM, The Netherlands, May 27, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present a corporate overview at the Jefferies 2015 Global Healthcare Conference, to be held in New York City, June 1-4
Read more →QUREuniQure Announces Closing of Strategic Collaboration with Bristol-Myers Squibb to Develop Gene Therapies for Cardiovascular Disease -Closing Triggers $50 Million Payment to uniQure- Amsterdam, the N
uniQure Announces Closing of Strategic Collaboration with Bristol-Myers Squibb to Develop Gene Therapies for Cardiovascular Disease -Closing Triggers $50 Million Payment to uniQure- Amsterdam, the Netherlands, May 26, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human gene th
Read more →QUREuniQure Announces Closing of Strategic Collaboration with Bristol-Myers Squibb to Develop Gene Therapies for Cardiovascular Disease
AMSTERDAM, the Netherlands, May 26, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the closing of its strategic collaboration with Bristol-Myers Squibb to develop gene therapies for cardiovascular disease. The transaction was
Read more →QUREAnnual Report 2014 uniQure N.V. Amsterdam
Amsterdam, May 1, 2015 uniQure N.V. Annual Report 2014 Page Management Board Report Introductory Statements 3 Business Overview 6 Corporate Governance Report 24 Supervisory Board Members 30 Report of the Supervisory Board 33 Management Board 40 Report of the Management
Read more →QUREuniQure Announces Closing of Follow-on Public Offering Amsterdam, the Netherlands
uniQure Announces Closing of Follow-on Public Offering Amsterdam, the Netherlands, April 15, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the closing of its previously announced follow-on public offering of 3,000,000 ordinary shares at an off
Read more →QUREuniQure Announces Pricing of Follow-on Public Offering
AMSTERDAM, Netherlands, April 9, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the pricing of its follow-on public offering of 3,000,000 ordinary shares at price to the public of $29.50 per ordinary share. After deducting the
Read more →QUREThe following risk factor on page 14 of uniQure s 2014 Annual Report on Form 20-F, filed with the Securities and Exchange Commission on
The following risk factor on page 14 of uniQure s 2014 Annual Report on Form 20-F, filed with the Securities and Exchange Commission on April 7, 2014, has been revised to reflect information received on April 8, 2015, with respect to the ongoing post-approval review of our Glyber
Read more →QUREuniQure Announces Pricing of Follow-on Public Offering Amsterdam, the Netherlands
uniQure Announces Pricing of Follow-on Public Offering Amsterdam, the Netherlands, April 9, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the pricing of its follow-on public offering of 3,000,000 ordinary shares at price to the public of $29.5
Read more →QUREEXECUTION COPY uniQure N.V. 3,000,000 Ordinary Shares (Nominal Value 0.05 Per Share)
3,000,000 Ordinary Shares (Nominal Value 0.05 Per Share) UNDERWRITING AGREEMENT LEERINK PARTNERS LLC COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o LEERINK PARTNERS LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o COWEN AND CO
Read more →QUREuniQure Announces Launch of Follow-on Public Offering AMSTERDAM
uniQure Announces Launch of Follow-on Public Offering AMSTERDAM, THE NETHERLANDS, Apr. 7, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it has commenced a follow-on public offering of 3,000,000 of its ordinary shares. All ordinary shares
Read more →QUREBristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases (New York and Amsterdam, the Netherlands
Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases (New York and Amsterdam, the Netherlands, April 6, 2015) Bristol-Myers Squibb Company (NYSE:BMY) and uniQure N.V. (NASDAQ:QURE) announced today an
Read more →QUREuniQure Announces Results for Fourth Quarter and Financial Year 2014 Amsterdam, the Netherlands
uniQure Announces Results for Fourth Quarter and Financial Year 2014 Amsterdam, the Netherlands, April 6, 2015 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced unaudited results for the fourth quarter and year ending December 31, 2014, and provided an
Read more →QUREuniQure Announces Webcast to Discuss Bristol-Myers Squibb Collaboration
AMSTERDAM, The Netherlands, April 6, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that at 8:30 EDT/14:30 CET today April 6, 2015, the Company will host a live webcast presentation and conference call to discuss the collabora
Read more →QUREUNIQURE N.V. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following is a discussion of our financial condition and results of operations for the nine months ended
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following is a discussion of our financial condition and results of operations for the nine months ended September 30, 2014. You should read the following discussion and analysis together
Read more →QUREuniQure to Present at the at the Cowen and Company 35th Annual Health Care Conference
Amsterdam, The Netherlands, Feb. 23, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present a corporate overview at the Cowen and Company 35th Annual Healthcare Conference March 2-4, 2015, to be held
Read more →QUREuniQure to Present at the at the Leerink Partners Global Healthcare Conference
AMSTERDAM, the Netherlands, Feb. 6, 2015 (GLOBE NEWSWIRE) -- uniQure to Present at the at the Leerink Partners Global Healthcare Conference Amsterdam, the Netherlands, February 6, 2015 - uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its manage
Read more →QUREuniQure Appoints Matthew Kapusta as Chief Financial Officer Company Announces Changes in Supervisory Board and US-based Leadership Amsterdam, the Netherlands
uniQure Appoints Matthew Kapusta as Chief Financial Officer Company Announces Changes in Supervisory Board and US-based Leadership Amsterdam, the Netherlands, January 9, 2015 uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Matthew Kapusta has j
Read more →QUREuniQure Appoints Matthew Kapusta as Chief Financial Officer
AMSTERDAM, the Netherlands, Jan. 9, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Matthew Kapusta has joined uniQure's management team as Chief Financial Officer effective January 1, 2015. Mr. Kapusta brings to the Comp
Read more →QUREuniQure to Present at the Oppenheimer 25th Healthcare Conference - NYC
AMSTERDAM, The Netherlands, Dec. 5, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present at the Oppenheimer 25th Healthcare Conference - NYC, to be held December 10-11, 2014, at The Crowne Plaza Hot
Read more →QUREuniQure Announces Results for the Third Quarter of 2014 Amsterdam, the Netherlands
uniQure Announces Results for the Third Quarter of 2014 Amsterdam, the Netherlands, December 01, 2014 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced results for the third quarter of 2014. Corporate Highlights and Pipeline Program Updates Hemophili
Read more →QUREuniQure Announces Results for the Third Quarter of 2014
Amsterdam, The Netherlands, Dec. 1, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced results for the third quarter of 2014. Corporate Highlights and Pipeline Program Updates Hemophilia B Program - uniQure is finalizing all reg
Read more →QUREuniQure to Host Investor Day in New York City
Amsterdam, The Netherlands, Nov. 21, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that it will be hosting an Investor Day and simultaneous webcast in New York City on December 1, 2014, starting at 8:30 a.m. uniQure managemen
Read more →QUREuniQure to Present at Jefferies Global Healthcare Conference - London
AMSTERDAM, The Netherlands, Nov. 10, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that J rn Aldag, CEO, will present a corporate overview at Jefferies Global Healthcare Conference - London, to be held November 19-20, 2014.
Read more →QUREuniQure to Present at the Leerink Partners Rare Disease Roundtable Conference
Amsterdam, The Netherlands, Sept. 25, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present at the Leerink Partners Rare Disease Roundtable Conference, October 1st, 2014, to be held at the Le Parker M
Read more →QUREUNIQURE N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Balance Sheets as of
Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Balance Sheets as of December 31, 2013 and June 30, 2014 F-2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended June 30, 2013 (as resta
Read more →QUREuniQure Announces Results for the Second Quarter and First Half of 2014 and Provides Update on Gene Therapy Programs
AMSTERDAM, the Netherlands, Sept. 2, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced results for the second quarter of 2014 and an update on multiple gene therapy programs. Corporate Highlights In July, uniQure announced the
Read more →QUREuniQure Acquires Cardiology Gene Therapy Company InoCard
AMSTERDAM, Netherlands, Aug. 11, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardia
Read more →QUREChiesi and uniQure Provide Update on Glybera Launch Amsterdam, the Netherlands, and Parma, Italy
Chiesi and uniQure Provide Update on Glybera Launch Amsterdam, the Netherlands, and Parma, Italy, August 4, 2014 uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ( Chiesi ), a leading international pharmaceutical company, today provided
Read more →QUREuniQure Secures Additional $10M Venture Loan from Hercules Capital Restructured Venture Debt Financing for Expansion and Advancement of Gene Therapy Pipeline Amsterdam, the Netherlands
uniQure Secures Additional $10M Venture Loan from Hercules Capital Restructured Venture Debt Financing for Expansion and Advancement of Gene Therapy Pipeline Amsterdam, the Netherlands, July 1, 2014 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced th
Read more →QUREuniQure Secures Additional $10M Venture Loan from Hercules Capital
AMSTERDAM, the Netherlands, July 1, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the closing of an additional $10 million venture debt loan with Hercules Technology Growth Capital, Inc. (HTGC), increasing the total loan amo
Read more →QUREuniQure Announces Will Lewis as New Board Member
AMSTERDAM, Netherlands, June 12, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that Will Lewis has joined uniQure's Supervisory Board as of June 11th, 2014. Mr. Lewis has been serving as President and Chief Executive Officer
Read more →QUREUNIQURE N.V. Index to Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Balance Sheets as of
Index to Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Balance Sheets as of December 31, 2013 and March 31, 2014 F-2 Unaudited Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2013 and 2014 F-3 Unaudited
Read more →QUREuniQure Announces Results for the First Quarter 2014
--Platform Positioned to Develop the Next Generation of Novel Gene Therapies-- AMSTERDAM, The Netherlands, June 6, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced results for the first quarter of 2014. As of March 31, 2014, t
Read more →QUREuniQure Announces Analysis of Six-Year Follow-up Data for Glybera(R)
--50% Fewer Pancreatitis Events, No Severe Pancreatitis Post One-time Treatment-- AMSTERDAM, The Netherlands, June 3, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the full analysis of the six-year follow-up data for patient
Read more →QUREuniQure and Medison Sign Glybera(R) Distribution Agreement for Israel
AMSTERDAM, The Netherlands and PETACH TIKVA, Israel, May 29, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, and Medison Pharma Ltd., Israel's leading international healthcare marketing group, today announced an exclusive distribution agreemen
Read more →QUREuniQure Announces Successful Transfection of Liver Cells with AAV5 and Strong Safety Data from Acute Intermittent Porphyria Clinical Trial
--Phase I Interim Results of AMT-021 Presented at ASGCT Conference-- AMSTERDAM, The Netherlands, May 27, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced successful transfection of liver cells with the porphobilinogen deaminas
Read more →QURENotice to convene the Annual General Meeting of Shareholders of uniQure N.V. To be held at and organized by uniQure N.V. (the Company ), having its address at Meibergdreef 61, 1105 BA Amsterdam Zuid-Oost, the Netherlands
Notice to convene the Annual General Meeting of Shareholders of uniQure N.V. To be held at and organized by uniQure N.V. (the Company ), having its address at Meibergdreef 61, 1105 BA Amsterdam Zuid-Oost, the Netherlands, at 11:30 hrs CET on Wednesday 11 June 2014. Shareholders
Read more →QUREuniQure to Present at the BioEquity Europe and Jefferies Global Healthcare Conferences
AMSTERDAM, The Netherlands, May 15, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present a corporate overview at the 15th BioEquity Europe Conference, May 21-22, 2014, to be held at the Hilton Amste
Read more →QUREuniQure Announces Changes in Management Team
AMSTERDAM, The Netherlands, April 9, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Eric Goossens as its new Chief Operating Officer with a primary responsibility for manufacturing and project management. Mr
Read more →QUREuniQure Announces Changes in Management Team Amsterdam, the Netherlands
uniQure Announces Changes in Management Team Amsterdam, the Netherlands, April 9, 2014 uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced the appointment of Eric Goossens as its new Chief Operating Officer with a primary responsibility for manufacturing
Read more →QUREuniQure Announces Results for Financial Year 2013
AMSTERDAM, The Netherlands, March 26, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced unaudited results for the financial year ended December 31, 2013. As of December 31, 2013, the Company held cash and cash equivalents of 23.8
Read more →QUREuniQure Announces Results for Financial Year 2013 Amsterdam, the Netherlands
uniQure Announces Results for Financial Year 2013 Amsterdam, the Netherlands, March 26, 2014 uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced unaudited results for the financial year ended December 31, 2013. As of December 31, 2013, the Company held c
Read more →QUREuniQure to Present at Future Leaders in Biotech Conference
Amsterdam, The Netherlands, March 21, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present a corporate overview at the 21st Annual Future Leaders in the Biotech Industry Conference March 28, 2014, to
Read more →QUREuniQure and Chiesi Announce Six Year Follow-up Data from Glybera(r) Treated Patients
AMSTERDAM, Netherlands, March 17, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading international pharmaceutical company, today announced initial analysis of retrospectively collected individ
Read more →QUREuniQure Announces Closing of Initial Public Offering
AMSTERDAM, The Netherlands, Feb. 10, 2014 (GLOBE NEWSWIRE) -- uniQure B.V. ("uniQure"), a leader in human gene therapy, today announced the closing of its previously announced initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per o
Read more →QUREuniQure Announces Pricing of Initial Public Offering
Amsterdam, The Netherlands, Feb. 5, 2014 (GLOBE NEWSWIRE) -- uniQure B.V. ("uniQure"), a leader in human gene therapy, today announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share. In addi
Read more →Competitive Position
How QURE ranks across every disease it competes inCompetitive Position is a premium feature
See how QURE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial